The European Multidisciplinary Cancer Congress
Integrating basic & translational science, surgery, radiotherapy, medical oncology & care

STOCKHOLM, 23-27 SEPTEMBER 2011
ADVANCE PROGRAMME & CALL FOR ABSTRACTS

www.ecco-org.eu
The Organising Committee would like to gratefully acknowledge the vital support, willing and collaboration of all Member Societies of ECCO – the European CanCer Organisation, without which this Congress would not be possible.

Acknowledgement

The Organising Committee would like to gratefully acknowledge the vital support, willing and collaboration of all Member Societies of ECCO – the European CanCer Organisation, without which this Congress would not be possible.

Official Media Partners

On behalf of the Executive Scientific Committee, we would like to acknowledge the collaboration and support of our official media partners:
# Table of Contents

- **Chairs’ Welcome** .................................................. 2
- **Save the Dates** ................................................... 3
- **Congress Committees** .......................................... 4
- **Scientific Programme** .......................................... 5
  - Programme at a Glance ........................................ 5
  - Programme Frames ............................................. 6
  - Detailed Advance Programme ............................... 10
- **Call for Abstracts** ............................................. 33
  - Abstract Policies & Regulations .......................... 33
  - Abstract Preparation & Submission ..................... 33
  - Abstract Selection Process ................................ 35
  - Late Breaking Abstracts – Policy & Regulations .... 35
  - Embargo Policy .................................................. 36
  - Abstract Topic Categories .................................. 37
- **Fellowship Grants & Educational Awards** .............. 40
- **Registration** .................................................... 42
- **Registration Form** ............................................ 43
- **Scientific Programme Tracks: Chairs & Experts** ...... 45
- **General Information** ......................................... 47
- **Top 10 Reasons to Attend** ................................ 49
- **Accommodation & Local Services** ....................... 50
- **Accommodation Form** ........................................ 51
Chairs’ Welcome

The first jointly organised multidisciplinary Cancer Congress – ECCO 15 – ESMO 34, Berlin, September 21 -24 2009, marked an important milestone in advancing cancer research and treatment across Europe by drawing a record multi-stakeholder audience of almost 15,000 participants, and presenting more cutting-edge and late breaking data than ever before.

Thanks to the vision, expertise and dedication of over 150 leading experts, who have tirelessly worked together to devise a comprehensive Scientific Programme of excellence synonymous with our Congresses, we can and will do even better.

The 2011 European Multidisciplinary Cancer Congress: the multidisciplinary mass gathering and celebration of European basic, translational and clinical studies

Building on the great successes of our Congresses past, as of this year we are bringing together the 16th ECCO, 36th ESMO, 30th ESTRO Congresses to form the European Multidisciplinary Cancer Congresses, organised in partnership with the essential contribution of all ECCO’s other Founding Members - ESSO, EACr, EONS and SIOPE. Further, as the Congress tagline ‘Integrating basic & translational science, surgery, radiotherapy, medical oncology & care’ suggests, the uniqueness of our Congresses lies in the multidisciplinary and multi-professional scope, appeal and draw.

The European Multidisciplinary Cancer Congresses are consequently the only multidisciplinary and multi-professional educational opportunity in oncology to take place in Europe – a fact that underpins the relevance, role and participation of each and every specialty in oncology.

Collectively advancing European cancer therapeutics and prevention: the 2011 European Multidisciplinary Cancer Congress Call for Abstracts

While the Scientific Programme will unquestionably deliver breakthrough advances and insight in scientific and clinical research, patient management and practice through an outstanding range of scientific and educational symposia, special sessions, teaching lectures, workshops, legendary ‘heated’ oxford style debates and more, the best discussions will also be triggered by your abstracts.

Only with your results will we be able to ultimately impact directly on our patients through more effective prevention strategies, earlier diagnosis and better treatment modalities, as well as succeed in bringing cutting edge data back to Europe.

In the hope that you will select our meeting - the largest European platform at which to present the latest, ground-breaking data, as your definitive choice, we invite you to submit your practice changing data which will be mature in 2011.

Just some of the results we want to see in Stockholm include those from practice-changing prospective Phase III clinical trials, Phase II studies showing anti-tumour activity in a novel context, early clinical trials with novel proof-of-principle data, and demonstrations of novel cancer biology with therapeutic implications.

The Scientific Programme: a 33 Track educational opportunity

In 2009 we promised a Scientific Programme of ‘firsts’ – our 2011 Congress will continue the trend. To further guarantee the multidisciplinary and multi-professional appeal unique to our Congresses we have incorporated 5 brand new Tracks including Industry as well as Oncotechnology.

Introduced to enhance the multidisciplinarity and multi-professional appeal of the Congress, these Tracks will present new technologies including new diagnostic equipment, advanced radiotherapy technologies, tele-oncology development and novel options for laboratory research that are of key to improving strategies in both patient care and in cancer research.

As the premier European cancer meetings, it is a logical consequence that each Congress builds on successes of the past by broadening in spectrum and scope, thereby setting new standards within the international cancer conference arena.

Launched at our 2009 Congress, the Oncopolicy Track will continue to embrace all stakeholders to address and tackle issues of prime importance to the European cancer community head-on, as well as promote and foster continued improvement at EU Level.

Similarly, both the Patient Advocacy/Ethics Track and the Oncology Nursing Track will continue to be fully integrated within the core Scientific Programme to ensure that we can all participate in discussion on issues of shared concern to cancer patients, advocates and professionals as well as allow for the participation of cancer nurses in all Programme sessions which will be imperative in identifying future directions aimed at improved patient care across Europe.

Totalling at 33 Tracks, the Scientific Programme has been structured to serve multidisciplinarity through the essential interconnectivity between all disciplines, professions and individual tumour types. No stone has been left unturned – this meeting is a must-attend for all!

In the trust that you will agree with us, we look forward to receiving your registration, reviewing your exciting data, and to collectively advancing European cancer therapeutics and prevention at the 2011 European Multidisciplinary Cancer Congress, 23 – 27 September 2011, Stockholm.

Michael Baumann, ECCO President and Congress Chair

David Kerr, ESMO President

Jean Bourhis, ESTRO President

Anne-Lise Børresen-Dale, Scientific Co-Chair (ECCO)

Jean Charles Soria, Scientific Co-Chair (ESMO)

Roger Henriksson, National Organising Committee Chair
Save the Dates

Registration
Early Rate Registration Closes (receipt of payment)  4 April 2011
Regular Rate Registration Closes (receipt of payment)  8 August 2011

Abstract Submission
Regular Abstract Submission Opens  31 January 2011
Regular Abstract Submission Closes  18 April 2011
Late Breaking Abstract Submission Opens  27 July 2011
Late Breaking Abstract Submission Closes  10 August 2011
Fellowship Grant Application Closes  18 April 2011
Housing Reservation Closes  1 August 2011

Congress Secretariat & Venue

Congress Secretariat
c/o ECCO – the European CanCer Organisation
Avenue E. Mounier 83
B-1200 Brussels
Tel: +32 (0)2 775 02 01
Fax: +32 (0)2 775 02 00
Email: stockholm2011@ecco-org.eu

Congress Venue
Stockholmsmässan
Mässvägen 1 (visitor’s address)
SE-125 80 Stockholm, Sweden
Tel: +46 (0)8 749 41 00

Exhibition & Sponsorship
The 2011 European Multidisciplinary Cancer Congress Exhibition represents an essential and integral element of the Congress, providing participants with an excellent platform for networking as well as perfect opportunity to gain further insight into cutting edge technology, latest healthcare solutions and services within the oncology field.

For information about sponsorship and exhibition opportunities please contact: Bruno De Man,
Email: bruno.deman@ecco-org.eu, Tel: +32 (0)2 775 02 04.

To download the Invitation to Industry brochure and view the exhibition floor plan please visit the ECCO website at: www.ecco-org.eu.

Accreditation for Continuous Medical Education (CME)
Application for accreditation has been submitted to the Accreditation Council of Oncology in Europe (ACOE).
**Congress Committees**

**Organising Committee**
- Michael Baumann (DE)  
- David Kerr (UK)  
- Jean Bourhis (FR)  
- Cornelius J. van de Velde (NL)  
- Anne-Lise Børresen-Dale (NO)  
- Jean Charles Soria (FR)  
- Roger Henriksson (SE)  

**ECCO President & Congress Chair**

**ESMO President & ECCO Board Member**

**ESTRO President**

**ECCO President Elect**

**Co-Scientific Chair & ECCO Treasurer (ECCO)**

**Co-Scientific Chair (ESMO)**

**National Organising Committee Chair**

**Executive Scientific Programme Committee**
- Anne-Lise Børresen-Dale (NO)  
- Jean Charles Soria (FR)  
- Jean Bourhis (FR)  
- Peter Naredi (SE)  
- Dirk Schrijvers (BE)  
- Rolf Stahel (CH)  
- Roger Henriksson (SE)  
- Michael Baumann (DE)  
- David Kerr (UK)  

**Co-Scientific Chair (ECCO)**

**Co-Scientific Chair (ESMO)**

**Radiotherapy Vice Chair**

**Surgery Vice Chair**

**Co-Education Chair**

**National Organising Committee Chair**

**ECCO President & Congress Chair**

**ESMO President & ECCO Board Member**

**National Organising Committee**
- Roger Henriksson  
- Håkan Mellstedt  

**Chair**

**Vice Chair**

**National Organising Committee Members**
- Jonas Bergh  
- Michael Bergqvist  
- Åke Borg  
- Jan-Erik Damber  
- Gunilla Enblad  
- Bengt Glimelius  
- Per Hall  
- Johan Hansson  
- Håkan Hedman  
- Matthias Löhr  
- Elisabeth Åvall Lundqvist  
- Beatrice Melin  
- Peter Naredi  
- Sten Nilsson  
- Monica Nister  
- Arne Östman  
- Göran Roos  
- Lena Sharp  
- Anders Widmark  
- Björn Zackrisson  

**Please see page 45 for Track Chairs & Experts**
Scientific Programme: Programme at a Glance

Registration Opening Hours

<table>
<thead>
<tr>
<th>Date</th>
<th>Opening Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thursday 22 September</td>
<td>07:00 – 19:00</td>
</tr>
<tr>
<td>Friday 23 September</td>
<td>08:00 – 21:00</td>
</tr>
<tr>
<td>Saturday 24 September</td>
<td>07:00 – 18:00</td>
</tr>
<tr>
<td>Sunday 25 September</td>
<td>07:00 – 18:00</td>
</tr>
<tr>
<td>Monday 26 September</td>
<td>07:00 – 18:00</td>
</tr>
<tr>
<td>Tuesday 27 September</td>
<td>07:00 – 12:00</td>
</tr>
</tbody>
</table>

Opening Event

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Friday 23</td>
<td>19:30-21:30</td>
</tr>
</tbody>
</table>

The 2011 Stockholm Cancer Congress Opening Event will take place on Friday 23 September from 19:30 onwards in Hall A1 of the Congress Centre.

In celebration of the largest and premier cancer meeting in Europe, we invite you to what promises to be an unforgettable evening in the company of friends and guests as well as enjoy a trio of live entertainment followed by a welcome reception serving local fare, delicacies and drinks.

Scientific Programme Sessions (*)

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday 24 September</td>
<td>08:00 – 18:00</td>
</tr>
<tr>
<td>Sunday 25 September</td>
<td>08:00 – 18:15</td>
</tr>
<tr>
<td>Monday 26 September</td>
<td>08:00 – 18:00</td>
</tr>
<tr>
<td>Tuesday 27 September</td>
<td>08:00 – 12:30</td>
</tr>
</tbody>
</table>

(*) All timings are subject to change. For updates on the programme please visit and bookmark ECCO’s website at: www.ecco-org.eu (select ‘Congresses and conferences,’ ‘2011 Stockholm Cancer Congress’)

Corporate Satellite Symposia

The 2011 Stockholm Cancer Congress Corporate Satellite Symposia are additional educational opportunities officially reviewed and approved by the Congress Scientific Committee. Offering multidisciplinary programmes to naturally complement the general concept of the official Scientific Programme, these sessions are the perfect forum for participants to discover the very latest scientific data and developments from with our industry.

To browse the Corporate Satellite Symposia agenda and add to your 2011 Stockholm Cancer Congress diary please see page 47.
## Saturday 24 September 2011

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>Opening Session</td>
<td>Welcome, Keynote Lectures</td>
</tr>
<tr>
<td>08:45</td>
<td>Breast Cancer in the Elderly: Different</td>
<td>Different Treatment modalities</td>
</tr>
<tr>
<td></td>
<td>Treatment Modalities</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Management of Local Recurrence of Rectal</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Management of Early Non-Small Cell Lung</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Radiotherapy of Prostate Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The Current Treatments of Nasopharyngeal</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cancer</td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td>Opening Session</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>Welcome, Award Session</td>
<td></td>
</tr>
<tr>
<td>11:15</td>
<td>Proffered paper session</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Proffered paper session</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Proffered paper session</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Proffered paper session</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Proffered paper session</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Proffered paper session</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Proffered paper session</td>
<td></td>
</tr>
<tr>
<td>13:45</td>
<td>Presidential I</td>
<td></td>
</tr>
<tr>
<td>14:15</td>
<td>Best and Late Breaking Abstracts</td>
<td></td>
</tr>
<tr>
<td>15:15</td>
<td>Peritoneal Surface Oncology - Evidence for</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Locoregional Treatment</td>
<td></td>
</tr>
<tr>
<td></td>
<td>The Management of Penile Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Immune System and Tumour Response to</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Radiotherapy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Late Toxicity Treatment of Head and Neck</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Issues in Economic Evaluation of New Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Therapies</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Too Little or Too Much Surgery for Melanoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Patient Information on Trial</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Adolescent and Young Adult Cancer Patients</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Are We Meeting Their Needs?</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Preventing Cervical Cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PET-Based Treatment Decisions in Hodgkin</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lymphoma</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Immunotherapy - the Future</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Monitoring Tumour Response to Therapy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- What Do the Images Tell Us?</td>
<td></td>
</tr>
<tr>
<td>15:45</td>
<td>Satellite Symposia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AES = Advocacy/Ethics - CRT = Court Room</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Trial - DEB = debate - TL = Teaching Lecture</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- E.S. = Educational Symposium - PP =</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Proffered Papers - S.S. = Scientific Symposi</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- SpecS = Special Session</td>
<td></td>
</tr>
</tbody>
</table>

**Satellite Symposia**

AES = Advocacy/Ethics - CRT = Court Room Trial - DEB = debate - TL = Teaching Lecture - E.S. = Educational Symposium - PP = Proffered Papers - S.S. = Scientific Symposium - SpecS = Special Session
### Programme at a Glance

**Sunday 25 September 2011**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>Highlights Session</td>
</tr>
<tr>
<td>08:45</td>
<td>Teaching Lecture</td>
</tr>
<tr>
<td>09:00</td>
<td>Breast, Colorectal, Lung, GU-Prostate, Nursing, Radiotherapy, Noncolorectal, Gynaecological, Head &amp; Neck, GU-other, Basic science, Haem., Melanoma, Paediatric, T.L.</td>
</tr>
<tr>
<td>11:00</td>
<td>Keynote</td>
</tr>
<tr>
<td>11:30</td>
<td>Do We Still need to Understand the Cancer Genome?</td>
</tr>
<tr>
<td>12:15</td>
<td>Best and Late Breaking Abstracts</td>
</tr>
<tr>
<td>14:15</td>
<td>Interactive Workshop</td>
</tr>
<tr>
<td>17:15</td>
<td>European Society for Medical Oncology (ESMO) - Awards Session</td>
</tr>
<tr>
<td>18:45</td>
<td>Satellite Symposium</td>
</tr>
</tbody>
</table>

**Abbreviations:**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Topics</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>Highlights Session</td>
<td>Male Breast Cancer – Négligént Tumour Disease</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Skin-Sparing Mastectomy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stage IIA Non-Small Cell Lung Cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Views by the Surgeon, Radiotherapist and Medical Oncologist</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Radiation Therapy and Radioisotopes for Bone Metastases. What's Their Real Benefit?</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CNS Drug Devel.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Symptom Science</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Elderly</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Paediatric</td>
</tr>
<tr>
<td></td>
<td></td>
<td>OncoTech</td>
</tr>
<tr>
<td>08:45</td>
<td>T.L. Interactive Session</td>
<td>Breast Surgical Radiotherapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lung Cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Noncolorectal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GU-Prostate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CNS</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Drug Devel.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Symptom Science</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Elderly</td>
</tr>
<tr>
<td>09:00</td>
<td>S.S.</td>
<td>C.O. Rectal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lung</td>
</tr>
<tr>
<td></td>
<td></td>
<td>General</td>
</tr>
<tr>
<td></td>
<td></td>
<td>GU-Prostate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nursing</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Cyno-logical</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Translational</td>
</tr>
<tr>
<td></td>
<td></td>
<td>OncoPolicy Forum</td>
</tr>
<tr>
<td></td>
<td></td>
<td>S.S.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PP</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PP</td>
</tr>
<tr>
<td></td>
<td></td>
<td>S.S.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>S.S.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>OncoPolicy Forum</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Spec.S</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Spec.S</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Spec.S</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Spec.S</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Spec.S</td>
</tr>
<tr>
<td>11:00</td>
<td>Keynote</td>
<td>From Cancer Care to Clinical Practice</td>
</tr>
<tr>
<td>12:30</td>
<td>Presidential II</td>
<td>Best and Late Breaking Abstracts</td>
</tr>
<tr>
<td>13:45</td>
<td></td>
<td>Breast Consration in Young Women With Early Breast Cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Medical Treatment of Metastatic Prostate Cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Contributes to Better Survival in Metastatic Prostate Cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Proffered paper session</td>
</tr>
<tr>
<td>14:15</td>
<td></td>
<td>GU-Prostate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Radiotherapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NOAcolorectal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nursing</td>
</tr>
<tr>
<td></td>
<td></td>
<td>General</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Industry</td>
</tr>
<tr>
<td>16:45</td>
<td>DEB</td>
<td>Breast Consration in Young Women With Early Breast Cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Medical Treatment of Metastatic Prostate Cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Contributes to Better Survival in Metastatic Prostate Cancer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Proffered paper session</td>
</tr>
<tr>
<td>17:00</td>
<td>DEB</td>
<td>DEB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DEB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DEB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DEB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DEB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DEB</td>
</tr>
<tr>
<td>18:00</td>
<td>DEB</td>
<td>DEB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DEB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DEB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DEB</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Spec.S</td>
</tr>
<tr>
<td>18:45</td>
<td></td>
<td>Interactive Workshop</td>
</tr>
</tbody>
</table>

**Satellite Symposia**

**Tuesday 27 September 2011**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00</td>
<td>Highlights Session</td>
</tr>
<tr>
<td></td>
<td><strong>BLUEROOM</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Teaching Lecture</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Interactive Session With Patient Cases</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Translational Surgical GU-Prostate</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Translational Genomics in Breast Cancer</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Overview on the role of Laparoscopic Surgery in Cancer Management</strong></td>
</tr>
<tr>
<td></td>
<td><strong>A Patient With a T2N0M0 Prostate Cancer, Gleason Score 7, PSA 19 µg/L - Views By the Urologist, Radiotherapist and Medical Oncologist</strong></td>
</tr>
<tr>
<td>08:45</td>
<td><strong>Breast Radiotherapy Nursing Noncolorectal</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Triple Negative Breast Cancer – How To Best Treat It and Prevent Relapse?</strong></td>
</tr>
<tr>
<td>09:00</td>
<td><strong>Symposium Science</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Lung Radiotherapy Nursing Noncolorectal Gynaecological Education</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Inequalities in Access to Drugs and Quality of Care</strong></td>
</tr>
<tr>
<td></td>
<td><strong>2010 Consensus On Lung Cancer: New Clinical Recommendations &amp; Current Status of Biomarker Assessment</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Partial Breast Irradiation</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Transitions in Care for Cancer Patients</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Hepatocellular Carcinoma: Novel Advancements in Diagnosis and Treatment</strong></td>
</tr>
<tr>
<td></td>
<td><strong>From Bench to Bedside in Ovarian Cancer</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Dealing With Children of Cancer Patients</strong></td>
</tr>
<tr>
<td>09:45</td>
<td><strong>Oncology Forum</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Proffered Paper Session</strong></td>
</tr>
<tr>
<td></td>
<td><strong>PARP Inhibiting Strategies From Molecular Mechanisms to Rational Clinical Application</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Unravelling Ras PI3 Kinases Targets</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Head and Neck Cancer in the Elderly Patient</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Managing the Side Effects</strong></td>
</tr>
<tr>
<td>11:00</td>
<td><strong>Special Session</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Breast Colorectal Lung Radiotherapy Nursing Noncolorectal Gynaecological Education</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Strategies of Prolonged Multimodality Treatment in Advanced Patients</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Treatment of T2N0M0 Non-Small Cell Lung Cancer in Patients Who Are Not Candidates for Lobectomy</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Stealstactic Radiotherapy for Liver Metastases</strong></td>
</tr>
<tr>
<td></td>
<td><strong>End of Life Care in Oncology</strong></td>
</tr>
<tr>
<td></td>
<td><strong>This House Believes That Chemotherapy Has No Further Role in the Treatment of Well Differentiated Neuroendocrine Tumours (NET)</strong></td>
</tr>
<tr>
<td></td>
<td><strong>This House Believes That Neoadjuvant Chemotherapy Should Become Standard of Care in Ovarian Cancer</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Surgical Treatment in Breast Cancer Patients With Distant Metastases</strong></td>
</tr>
<tr>
<td></td>
<td><strong>National Cancer Plans</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Desmoid Fibromatosus Tumours Representing An Unmet Medical Need</strong></td>
</tr>
<tr>
<td></td>
<td><strong>New insights in Metastatic Prostatic Processes</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Innovations in Early Clinical Trials</strong></td>
</tr>
<tr>
<td>12:30</td>
<td><strong>Young Oncology</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Innovations in Early Clinical Trials</strong></td>
</tr>
<tr>
<td></td>
<td><strong>This House Believes That Overall Survival is the Only Endpoint for Drug Approval</strong></td>
</tr>
<tr>
<td>17:00</td>
<td><strong>DEB= debate - E.S.= Educational Symposium - PP=Proffered Papers - S.S.= Scientific Symposium - Spec.S= Special Session - TL = Teaching Lecture</strong></td>
</tr>
</tbody>
</table>
Detailed Advance Programme

Basic Science

Saturday 24 September 2011

Teaching Lecture: Protein Homeostasis
- 08:00 - 08:45
  Speaker: T. Jung (Germany)

Scientific Symposium: Small RNAs and Cancer
- 11:15 - 13:15
  Chair: P.A. Sharp (USA)
  Chair: R.J. White (United Kingdom)
  Introduction
  Speaker: P.A. Sharp (USA)
  Tumourgenicity of MicroRNAs
  Speaker: R. Agami (The Netherlands)
  RNAi - Mechanism, Biology and Application to Cancer
  Speaker: C.M. Croce (USA)
  tRNA Control by Tumour Suppressors and Oncogenes
  Speaker: R.J. White (United Kingdom)
  Small RNA Regulators of Gene Expression
  Speaker: P.A. Sharp (USA)
  Concluding Remarks
  Speaker: R.J. White (United Kingdom)

Sunday 25 September 2011

Teaching Lecture: DNA Repair as Treatment Target
- 08:00 - 08:45
  Speaker: T. Helleday (United Kingdom)

Scientific Symposium: Tumour Microenvironment
- 09:00 - 11:00
  Chair: M.J. Bissell (USA)
  Chair: J.W. Pollard (USA)
  Introduction
  Speaker: J.W. Pollard (USA)
  Microenvironment in Breast Cancer
  Speaker: M.J. Bissell (USA)
  Stromal Cell Involvement in Cancer
  Speaker: J.W. Pollard (USA)
  Anticancer Approaches Based on Tumour Hypoxia and Metabolism
  Speaker: J. Pouyssegur (France)
  Tumour - Stroma Interactions in Breast Cancer Metastasis
  Speaker: C. Isacke (United Kingdom)
  Concluding Remarks
  Speaker: M.J. Bissell (USA)

Monday 26 September 2011

Special Session: Circulating Tumour Cells
- 13:15 - 14:15
  Chair: S. Sleijfer (The Netherlands)
  Technological Approaches for CTC Detection
  Speaker: C. Dive (United Kingdom)
  CTC and Micrometastases
  Speaker: K. Pantel (Germany)
  Markers for Circulating Tumour Cells
  Speaker: S. Sleijfer (The Netherlands)
  Discussion and Roundup

Tuesday 27 September 2011

Special Session: New Insights in Metastatic Processes
- 11:30 - 12:30
  Chair: S.A. Eccles (United Kingdom)
  Growth Control and Cancer Metastasis
  Speaker: S.A. Eccles (United Kingdom)
  Matrix Metalloproteases and Remodelling of the Extracellular Matrix
  Speaker: Z. Werb (USA)
  Intravital Imaging of Cancer Invasion and Resistance to Therapy
  Speaker: P. Friedl (The Netherlands)
  Discussion and Roundup

BREAST CANCER - EARLY AND ADVANCED DISEASE

Saturday 24 September 2011

Teaching Lecture: Breast Cancer in the Elderly: Different Treatment Modalities
- 08:00 - 08:45
  Speaker: R. Audisio (United Kingdom)

Educational Symposium: Metastatic Breast Cancer: What Do the Different Treatment Modalities Add to Survival?
- 16:00 - 18:00
  Chair: J.R. Johnston (United Kingdom)
  The Role of Surgery in Metastatic Breast Cancer
  Speaker: J. Ruiterkamp (The Netherlands)
  Radiotherapy in Patients With Metastatic Breast Cancer
  Speaker: W. Budach (Germany)
  Role of Hormonal Manipulations in Patients With Hormone-Sensitive Metastatic Breast Cancer
  Speaker: M. Castiglione-Gertsch (Switzerland)
  The Role of Chemotherapy and Targeted Agents in Patients With Metastatic Breast Cancer
  Speaker: S.R.D. Johnston (United Kingdom)

Sunday 25 September 2011

Teaching Lecture: How to Personalise Treatment in Early Breast Cancer
- 08:00 - 08:45
  Speaker: T. Sørlie (Norway)

Monday 26 September 2011

Teaching Lecture: Male Breast Cancer – Neglected Tumour Disease
- 08:00 - 08:45
  Speaker: F. Otto (Switzerland)

Scientific Symposium: How to Understand and to Reverse Drug Resistance in Metastatic Breast Cancer
- 09:00 - 11:00
  Chair: J. Bergh (Sweden)
  Chair: F. Andre (France)
  Introduction
  Speaker: J. Bergh (Sweden)
  Functional Genomic Approaches to the Dissection of Drug Resistance Mechanisms in Breast Cancer
  Speaker: S. Swanton (United Kingdom)
  Parp Inhibitors Sensitivity and Resistance
  Speaker: T. Helleday (United Kingdom)
How to Reserve the Resistance to Trastuzumab
Speaker: F. Andre (France)

mTOR an Attractive Drug Target in Breast Cancer: How to Reverse Resistance to mTOR Inhibitors
Speaker: J. Baselga (USA)

Concluding Remarks
Speaker: F. Andre (France)

Scientific Symposium: Breast Conservation in Young Women With Early Breast Cancer

14:45 - 16:45
Chair: U. Veronesi (Italy)
Chair: L. Pierce (USA)

Introduction
Speaker: U. Veronesi (Italy)

What Is the Role of Radiotherapy in Reducing Local Relapse Risk?
Speaker: L. Pierce (USA)

What Are the Sources of Local Relapse?
Speaker: M. Bollet (France)

What Are the Effects of Systemic Therapy in reducing Local Relapse Risk?
Speaker: S. Aebi (Switzerland)

Should Women under 35 Years Be Treated by Mastectomy?
Speaker: U. Veronesi (Italy)

Concluding Remarks
Speaker: L. Pierce (USA)

Debate: This House Believes that Small Biology-Driven Trials Will Substitute Large Randomised Clinical Trials in Breast Cancer

17:00 - 18:00
Moderator: R. Bristow (Canada)

Small Biology-Driven Trials Will Substitute Large Randomised Clinical Trials in Breast Cancer
Speaker: F. Andre (France)

Small Biology-Driven Trials Will NOT Substitute Large Randomised Clinical Trials in Breast Cancer
Speaker: D. F. Hayes (USA)

Small Biology-Driven Trials Will Substitute Large Randomised Clinical Trials in Breast Cancer
Second Against: M. Piccart (Belgium)

Questions and Answers Including Audience and Final Vote to See if Audience Have Changed their Opinion

Tuesday 27 September 2011

Teaching Lecture: Triple Negative Breast Cancer – How to Best Treat it and Prevent Relapse?
08:00 - 08:45
Speaker: A. Di Leo (Italy)

Special Session: Is the Biology of Metastatic Breast Cancer Similar to the Primary Breast Cancer?
11:30 - 12:30
Chair: I. Smith (United Kingdom)

Receptors and HER-2 to New Status Primary to Metastatic Intra Patients Difference?
Speaker: C. Viale (Italy)

Genomic Data on Metastatic Disease
Speaker: C. Klein (Germany)

Should Biopsy Be Done in Each Patient With a Suspicion of Metastatic Relapse?
Speaker: J. Bergh (Sweden)

Discussion and Roundup

Cancer in the Older Patient

Monday 26 September 2011

Teaching Lecture: Geriatrics and Haematological Malignancies
08:00 - 08:45
Speaker: C. Thieblemont (France)

Special Session: Health Status in Screening in Elderly Patients – Is This the Way Forward?
13:15 - 14:15
Chair: J. P. Droz (France)

Geriatric Evaluation Is the Principle Way of Assessing the Elderly Patients
Speaker: R. Bernabei (Italy)

The Use of Screening Tools in Geriatric Oncology
Speaker: M. Extermann (USA)

Discussion and Roundup

Tuesday 27 September 2011

Scientific Symposium: Head and Neck Cancer in the Elderly Patient
09:00 - 11:00
Chair: V. Gregoire (Belgium)
Chair: H. Langendijk (The Netherlands)

Introduction
Speaker: H. Langendijk (The Netherlands)

Epidemiology and the Practice of Treatment of the Elderly Patient in Head and Neck Cancer
Speaker: K. Syrigos (Greece)

Special Considerations in Surgery for Elderly Patients With Head and Neck Cancer
Speaker: J. Lefebvre (France)

Lack of Benefit of Intensified Treatment Strategies in Elderly Patients With Squamous Cell Head and Neck Cancer
Speaker: L. Licitra (Italy)

The Importance of Geriatric Assessment Using the ‘Frailty Index’ among Patients With Head and Neck Cancer Treated With Radiotherapy: Toxicity and Quality of Life
Speaker: H. Langendijk (The Netherlands)

Concluding Remarks
Speaker: M. Hegi (Switzerland)

Central Nervous System

Sunday 25 September 2011

Special Session: Endpoints in Clinical Trials
13:15 - 14:15
Chair: R. Grant (United Kingdom)

MR-Response Criteria in Neurooncology
Speaker: M. Bendszus (Germany)

Endpoints for Phase II Trials
Speaker: S. Chang (USA)

Endpoints for Phase III Trials
Speaker: M. J. van den Bent (The Netherlands)

Discussion and Roundup

Monday 26 September 2011

Teaching Lecture: Anaplastic Gliomas: An Emerging Entity
08:00 - 08:45
Speaker: W. Wick (Germany)

Scientific Symposium: Optimising Treatment in Gliomas
09:00 - 11:00
Chair: M. Hegi (Switzerland)
Chair: O. Chinot (France)

Introduction
Speaker: O. Chinot (France)

Molecular Biomarkers
Speaker: C. Brennan (USA)

Radiotherapy
Speaker: M. Mehta (USA)

Angiogenesis
Speaker: R. Bjerkvig (Norway)

Translational
Speaker: R. Stupp (Switzerland)

Clinical
Speaker: O. Chinot (France)

Concluding Remarks
Speaker: M. Hegi (Switzerland)
Debate: This House Believes That Radiotherapy in Brain Metastases Does Matter

17:00 - 18:00
Moderator: W. Grisold (Austria)
Radiotherapy in Brain Metastases Does Really Matter
Speaker in Favour: B. Baumert (The Netherlands)
Radiotherapy in Brain Metastases Does NOT Really Matter
Speaker Against: R. Soffietti (Italy)
Questions and Answers Including Audience and Final Vote to See If Audience Have Changed Their Opinion

DIAGNOSTIC / BIOMARKERS

MONDAY 26 SEPTEMBER 2011

Scientific Symposium: High Throughput Technology Platforms for Biomarker Discovery – State of the Art
14:45 - 16:45
Chair: L. Pusztai (USA)
Chair: V. Lazar (France)
Introduction
Speaker: L. Pusztai (USA)
Overview and Definition of Biomarkers (General Introduction)
Speaker: J. Reis-Filho (United Kingdom)
Role of Gene Expression Profiling for Biomarker Discovery
Speaker: L. Pusztai (USA)
Proteomics
Speaker: J. Lehto (Sweden)
Full Genome Sequence Analysis
Speaker: S. Aparicio (Canada)
Integration of System Biology and Bioinformatics in Cancer
Speaker: S.H. Friend (USA)
Concluding Remarks
Speaker: V. Lazar (France)

Debate: This House Believes That Whole Genome Sequencing Will Replace Conventional Histopathology in Diagnosis and Classification of Cancer
17:00 - 18:00
Moderator: M. Van de Vijver (The Netherlands)
Whole Genome Sequencing Will Replace Conventional Histopathology in Diagnosis and Classification of Cancer
Speaker in Favour: A.L. Børresen-Dale (Norway)
Whole Genome Sequencing Will Replace Conventional Histopathology in Diagnosis and Classification of Cancer
Speaker Against: E. Brambilla (France)
Whole Genome Sequencing Will NOT Replace Conventional Histopathology in Diagnosis and Classification of Cancer
Speaker Against: J.C. Soria (France)
Whole Genome Sequencing Will NOT Replace Conventional Histopathology in Diagnosis and Classification of Cancer
Speaker Against: G. Viale (Italy)
Questions and Answers Including Audience and Final Vote to See if Audience Have Changed Their Opinion

DRUG DEVELOPMENT

MONDAY 26 SEPTEMBER 2011

Teaching Lecture: Status of Therapeutic Anticancer Vaccines
08:00 - 08:45
Speaker: C.N. Baxevanis (Greece)

Debate: This House Believes That Using Markers in Early Clinical Trials Accelerate the Development Process of a New Drug
17:00 - 18:00
Moderator: E. Cohen-Jonathan-Moyal (France)
Using Markers in Early Clinical Trials Accelerate the Development Process of a New Drug
Speaker in Favour: J. Baselga (USA)
Using Markers in Early Clinical Trials Accelerate the Development Process of a New Drug
Speaker Against: L. Gianni (Italy)
Using Markers in Early Clinical Trials Accelerate the Development Process of a New Drug
Speaker Against: R. Marais (United Kingdom)
Using Markers in Early Clinical Trials Accelerate the Development Process of a New Drug
Speaker Against: E. Brambilla (France)
Questions and Answers Including Audience and Final Vote to See if Audience Have Changed Their Opinion

EDUCATION

SATURDAY 24 SEPTEMBER 2011

Teaching Lecture: Breast Cancer in the Elderly: Different Treatment Modalities
08:00 - 08:45
Speaker: R. Audisio (United Kingdom)

Teaching Lecture: Management of Local Recurrence of Rectal Cancer
08:00 - 08:45
Speaker: T. Wiggers (The Netherlands)

Teaching Lecture: Management of Early Non-Small Cell Lung Cancer
08:00 - 08:45
Speaker: T. Le Chevalier (France)

Teaching Lecture: What Are the Expected Developments in Medical Treatment of Bladder Cancer
08:00 - 08:45
Speaker: J. Bellmunt (Spain)

Teaching Lecture: Radiotherapy of Prostate Cancer
08:00 - 08:45
Speaker: A.T. Chan (Hong Kong)

Teaching Lecture: The Current Treatment of Nasopharyngeal Cancer
08:00 - 08:45
Speaker: J.S. de Bono (United Kingdom)

BRAF/KRAS Codrivers of Tumour Progression
Speaker: R. Marais (United Kingdom)
MEK-RAF Inhibitors
Speaker: D. Solit (USA)
P13 Kinases
Speaker: J. Tabernero (Spain)

Concluding Remarks
Speaker: P. Workman (United Kingdom)

Special Session: Innovations in Early Clinical Trials
11:30 - 12:30
Chair: S. Marsoni (Italy)
Phase O vs. Phase I – Ethics, Regs and Feasibility
Speaker: A. J. Murgo (USA)
Innovative Models to Optimise Phase I Development of Novel Anticancer Agents
Speaker: J. H. M. Schellens (The Netherlands)
Tackling Futility With Adaptive Designs
Speaker: M. Buyse (Belgium)
Discussion and Roundup
Teaching Lecture: To PET or Not to PET: What Are the Indications?
08:00 - 08:45
Speaker: S. Stroobants (Belgium)

Teaching Lecture: Advances in the Treatment of Myeloma
08:00 - 08:45
Speaker: M.A. Dimopoulos (Greece)

Teaching Lecture: Protein Homeostasis
08:00 - 08:45
Speaker: T. Jung (Germany)

Teaching Lecture: Current Standards and New Trends in the Primary Treatment of Colorectal Cancer
08:00 - 08:45
Speaker: C. Bokemeyer (Germany)

Teaching Lecture: Thymoma
08:00 - 08:45
Speaker: P. Baas (The Netherlands)

Teaching Lecture: New Adjuvant Treatments for Locally Advanced Prostate Cancer
08:00 - 08:45
Speaker: A. Horwich (United Kingdom)

08:00 - 08:45
Speaker: H. Kristeleit (United Kingdom)

Teaching Lecture: Adjuvant Chemotherapy and Radiation Therapy in High Risk Penile Cancer
08:00 - 08:45
Speaker: C. Theodore (France)

Teaching Lecture: New Technology in Radiotherapy
08:00 - 08:45
Speaker: J. Kazmierska (Poland)

Teaching Lecture: Growth Factor Receptor Related Therapy for Gastric Cancer
08:00 - 08:45
Speaker: A. Cervantes (Spain)

Teaching Lecture: Uterine Sarcomas: A Multidisciplinary Challenge
08:00 - 08:45
Speaker: P.G. Casali (Italy)

Teaching Lecture: Thyroid – Emerging Tumours
08:00 - 08:45
Speaker: M. Schlumberger (France)

Teaching Lecture: DNA Repair as Treatment Target
08:00 - 08:45
Speaker: T. Helleday (United Kingdom)

Teaching Lecture: How to Personalise Treatment in Early Breast Cancer
08:00 - 08:45
Speaker: T. Sørlie (Norway)

Teaching Lecture: Current Standards and New Trends in the Primary Treatment of Colorectal Cancer
08:00 - 08:45
Speaker: C. Bokemeyer (Germany)

Teaching Lecture: Diagnostic and Therapeutic Approach of Primary Cutaneous Lymphomas
08:00 - 08:45
Speaker: To Be Announced

Teaching Lecture: Current Approaches to Adjuvant Therapy of Melanoma
08:00 - 08:45
Speaker: S. Aamdal (Norway)

Teaching Lecture: Medulloblastoma
08:00 - 08:45
Speaker: L. Padovani (France)

Educational Symposium: Optimal Treatment for Advanced Ovarian Cancer
14:45 - 16:45
Chair: I.B. Vergote (Belgium)
Surgery: Primary or Neoadjuvant Therapy
Speaker: I.B. Vergote (Belgium)
First Line Therapy: Have We Made Any Improvement?
Speaker: M. Bookman (USA)
Optimal Treatment for Relapsed Disease
Speaker: J. Ledermann (United Kingdom)
The Role of Targeted Therapy in Ovarian Cancer
Speaker: S.B. Kaye (United Kingdom)

Educational Symposium: Screening for Cancer: Sense and Sensibilities
14:45 - 16:45
Chair: R.J. van Klaveren (The Netherlands)
Breast Cancer
Speaker: P. Autier (France)
Lung Cancer
Speaker: R.J. van Klaveren (The Netherlands)
Colorectal Cancer
Speaker: F.H. Schroeder (The Netherlands)

Interactive Workshop: What Knowledge and Attitudes Do Paid Carers of People With Learning Disabilities Have About Cancer?
15:00 - 16:00
Coordinator: D.E. Wyatt (United Kingdom)
Coordinator: P. Talbot (United Kingdom)

Monday 26 September 2011
Teaching Lecture: Male Breast Cancer – Neglected Tumour Disease
08:00 - 08:45
Speaker: F. Otto (Switzerland)
Teaching Lecture: Skin-Sparing Mastectomy  
■ 08:00 - 08:45  
Speaker: A.D. Baildam (United Kingdom)

Interactive Session With Patient Cases: Stage IIIa Non-Small Cell Lung Cancer - Views by the Surgeon, Radiotherapist and Medical Oncologist  
■ 08:00 - 09:00  
Chair: G. Giaccone (USA)  
Presentation of a Complex Case  
Speaker: G. Giaccone (USA)  
Surgeon’s Point of View  
Speaker: U. Pastorino (Italy)  
Radiotherapist’s Point of View  
Speaker: D. Zips (Germany)  
Medical Oncologist’s Point of View  
Speaker: B. Besse (France)  
Discussion and Roundup

Teaching Lecture: Radiation Therapy and Radioisotopes for Bone Metastases: What Is Their Real Benefit?  
■ 08:00 - 08:45  
Speaker: U. Nestle (Germany)

Teaching Lecture: Introduction to Lung Cancer Curriculum (Part 2): Epidemiology of Lung Cancer  
■ 08:00 - 08:45  
Speaker: S.J. O’Connor (The Netherlands)

Teaching Lecture: Cancer and Pregnancy: What Should We Know About the Management With Systemic Treatment of Pregnant Women With Cancer?  
■ 08:00 - 08:45  
Speaker: N. Pavlidis (Greece)

Teaching Lecture: Current Standards and New Trends in Esophageal Cancer  
■ 08:00 - 08:45  
Speaker: F. Lordick (Germany)

Teaching Lecture: Active Surveillance and Prostatectomy  
■ 08:00 - 08:45  
Speaker: C.H. Bangma (The Netherlands)

Teaching Lecture: Anaplastic Gliomas: An Emerging Entity  
■ 08:00 - 08:45  
Speaker: W. Wick (Germany)

Teaching Lecture: Status of Therapeutic Anticancer Vaccines  
■ 08:00 - 08:45  
Speaker: C.N. Baxevanis (Greece)

Teaching Lecture: Emergency and Palliative Care  
■ 08:00 - 08:45  
Speaker: D. Schrijvers (Belgium)

Teaching Lecture: Geriatrics and Haematological Malignancies  
■ 08:00 - 08:45  
Speaker: C. Thieblemont (France)

Educational Symposium: Medical Treatment of Metastatic Prostate Cancer  
■ 14:45 - 16:45  
Chair: B. Tombal (Belgium)  
What Is the Pathophysiology of a Hormone-Resistant Prostate Tumour?  
Speaker: B. Tombal (Belgium)  
Targeting the Androgen Receptor  
Speaker: J.S. de Bono (United Kingdom)  
Novel Treatments for Castration-Resistant Prostate Cancer  
Speaker: C.N. Sternberg (Italy)  
Experimental Models for Development of New Medical Treatments in Prostate Cancer  
Speaker: A. Chauchereau (France)  
Interactive Workshop: Dealing With Emotionally Challenging Patients or Families  
■ 17:00 - 18:00  
Coordinator: L. Fallowfield (United Kingdom)

Tuesday 27 September 2011

Teaching Lecture: Triple Negative Breast Cancer – How to Best Treat It and Prevent Relapse?  
■ 08:00 - 08:45  
Speaker: A. Di Leo (Italy)

Teaching Lecture: Combining Molecular Targeted Agents and Radiotherapy  
■ 08:00 - 08:45  
Speaker: T. Brunner (United Kingdom)

Teaching Lecture: Introduction to Lung Cancer Curriculum (Part 3): Chemotherapy in Lung Cancer  
■ 08:00 - 08:45  
Speaker: R. Lal (United Kingdom)

Teaching Lecture: Adjuvant Treatment of Pancreatic Cancer  
■ 08:00 - 08:45  
Speaker: J. Neoptolemos (United Kingdom)

Teaching Lecture: Translational Genomics in Breast Cancer  
■ 08:00 - 08:45  
Speaker: C. Caldas (United Kingdom)

Teaching Lecture: Overview on the Role of Laparoscopic Surgery in Cancer Management  
■ 08:00 - 08:45  
Speaker: P. Willemsen (Belgium)

Interactive Session With Patient Cases: A Patient With a T2N0M0 Prostate Cancer, Gleason Score 7, PSA 19 µg/L - Views by the Urologist, Radiotherapist and Medical Oncologist  
■ 08:00 - 09:00  
Chair: F.H. Schroeder (The Netherlands)  
Presentation of a Complex Case  
Speaker: F.H. Schroeder (The Netherlands)  
Urologist’s Point of View  
Speaker: J. Hugosson (Sweden)  
Radiotherapist’s Point of View  
Speaker: C. Parker (United Kingdom)  
Medical Oncologist’s Point of View  
Speaker: J. Bellmunt (Spain)  
Discussion and Roundup

Teaching Lecture: Soft Tissue Sarcomas: Are All Soft Tissue Sarcomas Treated With the Same Drugs?  
■ 08:00 - 08:45  
Speaker: J.Y. Blay (France)

■ 09:00 - 11:00  
Chair: R. Stahel (Switzerland)  
First Line  
Speaker: C. Gridelli (Italy)  
Second Line  
Speaker: F. De Marinis (Italy)  
Early Locally Advanced Disease  
Speaker: V. Weder (Switzerland)  
SCLC  
Speaker: C. Le Pechoux (France)
Chair: P. Hall (Sweden)

Concluding Remarks
Speaker: M. Esteller (Spain)

Epigenomics in Population Studies
Speaker: P. Vineis (United Kingdom)

Studies’ (EWAS) the Missing Piece?
Are ‘Environmental Wide Association Diving Genome?
Genetic Susceptibility: Are We Surfing or

GLOBOCAN 2008 Cancer Incidence and Mortality in Europe –

Chair: C.P. Wild (France)

16:00 - 18:00

Epidemiology - the Next Generation
Scientific Symposium: Molecular Cancer Epidemiology - the Next Generation

Saturday 24 September 2011

Special Session: Preventing Cervical Cancer
14:15 - 15:15
Chair: J. Dillner (Sweden)

Prospects for Rapid Worldwide Reduction of Cervical Cancer
Speaker: J. Peto (United Kingdom)

Cervix Cancer Vaccination
Speaker: J. Cuzick (United Kingdom)

Cervix Cancer Screening - European Guidelines
Speaker: L. Von Karsa (France)

Discussion and Roundup

Scientific Symposium: Molecular Cancer Epidemiology - the Next Generation
16:00 - 18:00
Chair: C.P. Wild (France)

Introduction
Speaker: C.P. Wild (France)

Cancer Incidence and Mortality in Europe – GLOBOCAN 2008
Speaker: D. Forman (France)

Genetic Susceptibility: Are We Surfing or Diving Genome?
Speaker: P. Pharoah (United Kingdom)

Are ‘Environmental Wide Association Studies’ (EWAS) the Missing Piece?
Speaker: P. Vines (United Kingdom)

Epigenomics in Population Studies
Speaker: M. Esteller (Spain)

Concluding Remarks
Speaker: P. Hall (Sweden)

Sunday 25 September 2011

Special Session: Calories and Cancer
13:15 - 14:15
Chair: A. Cescher (United Kingdom)

Body Mass Index and Cancer Incidence
Speaker: A.G. Renahan (United Kingdom)

Biochemical Consequence of Caloric Restriction
Speaker: V.O. Longo (USA)

Energy Balance Including Physical Activity Influence Breast and Colon Carcinogenesis - Results From Recent Studies
Speaker: J. Thune (Norway)

Discussion and Roundup

GASTROINTESTINAL MALIGNANCIES - COLORECTAL CANCER

Saturday 24 September 2011

Teaching Lecture: Management of Local Recurrence of Rectal Cancer
08:00 - 08:45
Speaker: T. Wiggers (The Netherlands)

Educational Symposium: The Jungle of Treatments in Advanced Colorectal Cancer
16:00 - 18:00
Chair: C.J.H. van de Velde (The Netherlands)

Conversion and Neoadjuvant Chemotherapy
Speaker: C. Folprecht (Germany)

Treatment of PsA and Rapidly Progressive Disease
Speaker: C. Verhoef (The Netherlands)

The Treatment of Patients With Low Tumour Burden and/or Slow Growing Disease
Speaker: T.S. Maughan (United Kingdom)

Re-Challenge and the Concept of the Number Lines Therapy
Speaker: A. de Gramont (France)

Sunday 25 September 2011

Teaching Lecture: Current Standards and New Trends in the Primary Treatment of Colorectal Cancer
08:00 - 08:45
Speaker: C. Bokemeyer (Germany)

Scientific Symposium: Tailored Chemotherapy in Colon Cancer
14:45 - 16:45
Chair: E. Van Cutsem (Belgium)
Chair: P. Rougier (France)

Introduction
Speaker: E. Van Cutsem (Belgium)

The Genomic and Stem Cell Perspective
Speaker: I. Tomlinson (United Kingdom)

The Role of Microsatellite Instability in the Era of Personalised Medicine
Speaker: E. Vilar (USA)

Optimal Approach on the KRAS Wild Type
Speaker: P. Rougier (France)

Optimal Approach of the KRAS Mutant
Speaker: E. Van Cutsem (Belgium)

The Angiogenesis Inhibition
Speaker: M. Dicato (Luxembourg)

Concluding Remarks
Speaker: P. Rougier (France)

Monday 26 September 2011

Scientific Symposium: Tailored Neoadjuvant Therapy in Rectal Cancer
09:00 - 11:00
Chair: V. Valentini (Italy)
Chair: L. Påhlman (Sweden)

Introduction
Speaker: L. Påhlman (Sweden)

Tailored Neoadjuvant Therapy According to Initial Staging Versus Biology Predictors
Speaker: K. Haustermans (Belgium)

Tailored Therapy During Neoadjuvant Treatment
Speaker: V. Valentini (Italy)

Tailored Surgery According to Clinical Response
Speaker: J.C. Guillen (USA)

Tailored Adjuvant Chemotherapy According to Pathological Response
Speaker: W. Scheithauer (Austria)

Tailored Follow-Up According to Staging Speaker: L. Påhlman (Sweden)

Concluding Remarks
Speaker: V. Valentini (Italy)

Debate: This House Believes That Transanal Endoscopic Microsurgery (TEM) / no Surgery is Reliable in Responder Rectal Cancer Patients After Preoperative Chemoradiation
17:00 - 18:00
Moderator: B. Climentus (Sweden)

TEM / no Surgery is Reliable in Responder Rectal Cancer Patients After Preoperative Chemoradiation Speaker in Favour: C. Coco (Italy)

TEM / no Surgery is NOT Reliable in Responder Rectal Cancer Patients After Preoperative Chemoradiation Speaker Against: C.J.H. van de Velde (The Netherlands)

TEM / no Surgery is Reliable in Responder Rectal Cancer Patients After Preoperative Chemoradiation Seconder in Favour: G. Lammering (The Netherlands)
TEM / no Surgery is NOT Reliable in Responder Rectal Cancer Patients After Preoperative Chemoradiation
Second Opinion Against: D. Sebag-Montefiore
(United Kingdom)

Questions and Answers Including Audience and Final Vote to See If Audience Have Changed Their Opinion

**Tuesday 27 September 2011**

Special Session: Strategies of Prolonged Multimodality Treatment in Advanced Patients
- 11:30 - 12:30
  - Chair: H. Schmoll (Germany)
  - Intermittent Treatment
    - Speaker: A. de Gramont (France)
  - Maintenance Treatment With Biologicals
    - Speaker: J. Tabernero (Spain)
  - Can We Consolidate Medical Response With Local Treatment
    - Speaker: P. Rougier (France)

Discussion and Roundup

**Gastrointestinal Malignancies - Non-Colorectal Cancer**

**Sunday 25 September 2011**

Teaching Lecture: Growth Factor Receptor Related Therapy for Gastric Cancer
- 08:00 - 08:45
  - Speaker: A. Cervantes (Spain)

**Monday 26 September 2011**

Teaching Lecture: Current Standards and New Trends in Esophageal Cancer
- 08:00 - 08:45
  - Speaker: F. Lordick (Germany)

Special Session: Management of Hilar and Intrahepatic Cholangiocarcinoma
- 13:15 - 14:15
  - Chair: R. Adam (France)
  - Surgical Resection of Hilar and Intrahepatic Cholangiocarcinoma
    - Speaker: O. Farges (France)
  - Liver Transplantation for Cholangiocarcinoma
    - Speaker: S. Jonas (Germany)
  - Adjuvant and Systemic Treatment of Advanced Cholangiocarcinoma
    - Speaker: J. Valle (United Kingdom)

Discussion and Roundup

**Tuesday 27 September 2011**

Teaching Lecture: Adjuvant Treatment of Pancreatic Cancer
- 08:00 - 08:45
  - Speaker: J. Neoptolemos (United Kingdom)

Scientific Symposium: Hepatocellular Carcinoma: Novel Advancements in Diagnosis and Treatment
- 09:00 - 12:00
  - Chair: J. Llovet (Spain)
  - Introduction
    - Speaker: V. Mazzaferro (Italy)
  - New Molecular Targeted Therapies
    - Speaker: J. Llovet (Spain)
  - Novel Imaging Techniques and Treatment Assessment for Evaluating Benefit From Targeted Agents
    - Speaker: V. Vilgrain (France)
  - Local Therapy for HCC
    - Speaker: E. Lartigau (France)
  - Liver Transplantation and Resection for HCC
    - Speaker: V. Mazzaferro (Italy)

Concluding Remarks
- Speaker: J. Llovet (Spain)

Debate: This House Believes That Chemotherapy Has No Further Role in the Treatment of Well Differentiated Neuroendocrine Tumours (NET)
- 11:30 - 12:30
  - Moderator: D. Cunningham (United Kingdom)
  - Chemistry Has No Role
    - Speaker in Favour: B. Wiedenmann (Germany)
    - Second Opinion Against: T. Meyer (United Kingdom)
    - Second Opinion in Favour: E. Raymond (France)
    - Second Opinion Against: M. Caplin (United Kingdom)

Questions and Answers Including Audience and Final Vote to See If Audience Have Changed Their Opinion

**General**

**Saturday 24 September 2011**

Opening Session
- 09:00 - 11:00
  - 09:00 - Welcome
    - Speaker: M. Baumann (Germany)
  - ESMO Welcome
    - Speaker: D. Kerr (United Kingdom)
  - ESTRO Welcome
    - Speaker: J. Bourhis (France)

Scientific Co-Chair
- Speaker: A. Cervantes (Spain)

**Scientific Co-Chair**
- Speaker: J. Baselga (USA)

**Metabolism and Cancer**
- Speaker: J. Bourhis (France)

**Limitations to Individualised Medicine**
- Speaker: To Be Announced

Presidential Session I: Best and Late Breaking Abstracts
- 12:30 - 14:30
  - ECCO - Pezcoller Award Lecture
  - Hamilton - Fairley Award Lecture
  - Late Breaking and Best Abstracts

Scientific Symposium: ECCO/ASCO Scientific Symposium
- 14:45 - 16:45
  - Session: To Be Announced

Society session: European Society for Medical Oncology (ESMO) - Awards Session
- 16:45 - 18:15
  - Chair: D. Kerr (United Kingdom)
The EAU Guidelines on Testicular Cancer  
Speaker: M.P. Laguna (The Netherlands)

What Is New in the Systemic Treatment of Urological Malignancies  
Speaker: P. Abrahamsson (Sweden)

Society Session: European Society of Surgical Oncology (ESSO) - Tailored Treatment for Older Cancer Patients - A Multidisciplinary Approach  
16:45 - 18:15  
Chair: P. Naredi (Sweden)

The ESSO Award Presented to Ricardo Audisio  
Award Lecturer: R.A. Audisio (United Kingdom)

Where and Why We Fail to Offer Appropriate Treatment to Older Cancer Patients  
Speaker: M. Jansen-Heijnen (The Netherlands)

Multimodal Tailored Treatment to Older Rectal Cancer Patients  
Speaker: H.J. Rutten (The Netherlands)

Cancer Clinical Trials in the Elderly: Are We Ageist?  
Speaker: B. Nordlinger (France)

General Discussion  
Speaker: R.A. Audisio (United Kingdom)

Society Session: European Society of Gynaecological Oncology (ESGO)  
16:45 - 18:15  
Session: To Be Announced

Society Session: European Society of Breast Cancer Specialists (EUSOMA)  
16:45 - 18:15

Age and Breast Cancer Discussion  
Speaker: B. Cutili (France)

The impact of age on breast cancer survival  
Speaker: A. Micheli (Italy)

Age, screening and high risk groups surveillance  
Speaker: R. Wilson (UK)

Eusoma Recommendations for the management of elderly women  
Speaker: L. Biganzoli (Italy)

Eusoma Recommendations for the management of young women  
Speaker: F. Cardoso (Portugal)

Society Session: European Association of Nuclear Medicine (EANM)  
16:45 - 18:15  
Session: To Be Announced

Society Session: European Association of Neuro-Oncology (EANO)  
16:45 - 18:15

The EANO Award presented to Kathy Oliver  
Chair: W. Grisold (Austria)

New Entities in Paraneoplastic Diseases  
Speaker: A. Vincent (United Kingdom)

How to Improve the Extent of Surgery With Better Neurological Function Preservation  
Speaker: L. Bella (Italy)

Quality of Life and Cognitive Function Monitoring  
Speaker: M. Klein (The Netherlands)

Stem Cells in Brain Tumours: Where Are We Going?  
Speaker: R. De Maria (Italy)

Society Session: The European Society for Paediatric Oncology (SIOP Europe)  
16:45 - 18:15

Proffered Paper Abstracts Will Be Presented in This Session

Society Session: European School of Oncology (ESO)  
16:45 - 18:15

Session: To Be Announced

The FAC Achievement Award Lecture  
Award Lecturer: To Be Announced

Questions and Answers

Concluding Remarks  
Speaker: To Be Announced

Society Session: The European Society of Nuclear Medicine (EANM)  
16:45 - 18:15

Session: To Be Announced

Society Session: European School of Oncology Pharmacy (ESOP)  
16:45 - 18:15

Session: To Be Announced
Monday 26 September 2011

Scientific Symposium: ESMO Clinical Practice Guidelines
- 09:00 - 11:00
  Introduction and ESMO Questionnaire by Session Chairs
  Chair: A. Cervantes (Spain)
  Chair: N. Pavlidis (Greece)
  Bladder Cancer Presentation
  Speaker: To Be Announced
  Bladder Cancer Discussion
  Speaker: To Be Announced
  Colorectal Cancer Presentation
  Speaker: To Be Announced
  Colorectal Cancer Discussion
  Speaker: To Be Announced
  Melanoma Presentation
  Speaker: To Be Announced
  Melanoma Discussion
  Speaker: To Be Announced
  Conclusions by Session Chairs

Keynote Lecture: How Registry Data Has Changed Rectal Cancer Treatment
- 11:30 - 12:15
  Speaker: L. Påhlman (Sweden)

Presidential Session III: Best and Late Breaking Abstracts
- 12:30 - 14:30
  Policy Makers Lecture
  Speaker: To Be Announced
  Late Breaking and Best Abstracts

Scientific Symposium: ESMO-JSMO Joint Symposium - What Can We Learn From Global Clinical Trials?
- 14:45 - 16:45
  Introduction by Session Chairs
  Chair: D. Kerr (United Kingdom)
  Chair: K. Tamura (Japan)
  Indox: Building a Collaborative Trials Network in India
  Speaker: D. Kerr (United Kingdom)
  Molecular Based Patient Selection in Global Clinical Trials for Non-Small Cell Lung Cancer
  Speaker: I. Ohamoto (Japan)
  Lessons from Global Clinical Trials for Gastric Cancer: Are They Steps Ahead?
  Speaker: A. Ohtsu (Japan)
  Industry-Led Global Trials - Do Benefits Outweigh Pitfalls?
  Speaker: S.J. Horning (USA)
  Conclusions by Session Chairs

Tuesday 27 September 2011

Scientific Symposium: Diabetes, Obesity and Cancer
- 14:45 - 16:45
  Session: To Be Announced

Tuesday 27 September 2011

Scientific Symposium: Diabetes, Obesity and Cancer
- 14:45 - 16:45
  Session: To Be Announced

Wednesday 28 September 2011

Scientific Symposium: New Insights in the Management of Renal Cancer
- 16:00 - 18:00
  Chair: S. Oudard (France)
  Chair: P. Hoskin (United Kingdom)
  Introduction
  Speaker: S. Oudard (France)
  Genetics of Clear Cell Renal Carcinoma
  Speaker: W.G. Kaelin, Jr (USA)
  Pharmaco-Economics
  Speaker: P. Clark (United Kingdom)
  New Approaches in Surgical Management of Renal Cancer
  Speaker: Z. Kirkali (Turkey)
  How to Integrate New Imaging Modalities
  Speaker: L. Fournier (France)
  New Agents in Renal Cancer
  Speaker: B. Escudier (France)
  Concluding Remarks
  Speaker: P. Hoskin (United Kingdom)

Sunday 25 September 2011

Teaching Lecture: Adjuvant Chemotherapy and Radiation Therapy in High Risk Penile Cancer
- 08:00 - 08:45
  Speaker: C. Theodore (France)

Special Session: Current Issues in the Management of Germ Cell Tumours
- 13:15 - 14:15
  Chair: M. De Santis (Austria)
  Relapse and Prognostic Factors
  Speaker: J. Beyer (Germany)
  Novel Targets and New Treatment
  Speaker: D.R. Feldman (USA)
  Cancer Survivorship
  Speaker: J. Oldenburg (Norway)
  Discussion and Roundup

Debate: This House Believes That Surgery Is the Mainstay for the Treatment of PT2 Bladder Cancer
- 15:00 - 16:00
  Moderator: J. Bellmunt (Spain)
  Surgery Is the Mainstay for the Treatment of PT2 Bladder Cancer
  Speaker in Favour: M. Wirth (Germany)
  Surgery Is NOT the Mainstay for the Treatment of PT2 Bladder Cancer
  Speaker Against: A. Zietman (USA)
  Surgery Is the Mainstay for the Treatment of PT2 Bladder Cancer
  Seconder Against: A. Kiltie (United Kingdom)
  Questions and Answers Including Audience and Final Vote to See if Audience Have Changed Their Opinion
GENITOURINARY MALIGNANCIES - PROSTATE CANCER

SUNDAY 25 SEPTEMBER 2011
Teaching Lecture: New Adjuvant Treatments for Locally Advanced Prostate Cancer
08:00 - 08:45
Speaker: A. Horwich (United Kingdom)

MONDAY 26 SEPTEMBER 2011
Teaching Lecture: Active Surveillance and Prostatectomy
08:00 - 08:45
Speaker: C.H. Bangma (The Netherlands)

Scientific Symposium: From New Targets to New Drugs in Prostate Cancer
09:00 - 11:00
Chair: J. Bellmunt (Spain)
Chair: N. Clarke (United Kingdom)
Introduction
Speaker: J. Bellmunt (Spain)
Bone Targeting
Speaker: K. Fizazi (France)
Androgen Receptor
Speaker: J. Bellmunt (Spain)
New Chemotherapy Agents
Speaker: O. Sartor (USA)
Other Targets
Speaker: K.N. Chi (Canada)
Concluding Remarks
Speaker: N. Clarke (United Kingdom)

Special Session: How Should We Treat Good Risk Prostate Cancer - Focally or Entirely?
13:15 - 14:15
Chair: T. de Reijke (The Netherlands)
Active Surveillance
Speaker: T. de Reijke (The Netherlands)
Brachytherapy - High Dose Rate or I-125?
Speaker: P. Hoskin (United Kingdom)
Heat, Ice and Light
Speaker: M. Emberton (United Kingdom)
Discussion and Roundup

Educational Symposium: Medical Treatment of Metastatic Prostate Cancer
14:45 - 16:45
Chair: B. Tombal (Belgium)

What Is the Pathophysiology of a Hormone-resistant Prostate Tumour?
Speaker: B. Tombal (Belgium)

Targeting the Androgen Receptor
Speaker: J.S. de Bono (United Kingdom)

Novel Treatments for Castration-Resistant Prostate Cancer
Speaker: C.N. Sternberg (Italy)

Experimental Models for Development of New Medical Treatments in Prostate Cancer
Speaker: A. Chouchereau (France)

Debate: This House Believes That the Combination of Multi-Modality Treatment is the Best Approach for the Treatment of High-Risk Prostate Cancer
17:00 - 18:00
Moderator: A. Bussi (France)
The Combination of Multi-Modality Treatment is the Best Approach for the Treatment of High-Risk Prostate Cancer
Speaker in Favour: C.N. Sternberg (Italy)
The Combination of Multi-Modality Treatment is NOT the Best Approach for the Treatment of High-Risk Prostate Cancer
Speaker Against: A. Heidenreich (Germany)
The Combination of Multi-Modality Treatment is the Best Approach for the Treatment of High-Risk Prostate Cancer
Seconder in Favour: B. Tombal (Belgium)
The Combination of Multi-Modality Treatment is NOT the Best Approach for the Treatment of High-Risk Prostate Cancer
Seconder Against: C. Parker (United Kingdom)
Questions and Answers Including Audience and Final Vote to See if Audience Have Changed Their Opinion

TUESDAY 27 SEPTEMBER 2011
Interactive Session With Patient Cases: A Patient With a T2N0M0 Prostate Cancer, Gleason Score 7, PSA 19 µg/L - Views by the Urologist, Radiotherapist and Medical Oncologist
08:00 - 09:00
Chair: F.H. Schroeder (The Netherlands)
Active Surveillance
Speaker: T. de Reijke (The Netherlands)
Brachytherapy - High Dose Rate or I-125?
Speaker: P. Hoskin (United Kingdom)
Heat, Ice and Light
Speaker: M. Emberton (United Kingdom)
Discussion and Roundup

Educational Symposium: Medical Treatment of Metastatic Prostate Cancer
14:45 - 16:45
Chair: B. Tombal (Belgium)

GYNÆCOLOGICAL CANCER

SUNDAY 25 SEPTEMBER 2011
Teaching Lecture: Uterine Sarcomas: A Multidisciplinary Challenge
08:00 - 08:45
Speaker: P.G. Casali (Italy)

Educational Symposium: Optimal Treatment for Advanced Ovarian Cancer
14:45 - 16:45
Chair: I.B. Vergote (Belgium)
Surgery: Primary or Neoadjuvant Therapy
Speaker: I.B. Vergote (Belgium)
First Line Therapy: Have We Made Any Improvement?
Speaker: M. Bookman (USA)
Optimal Treatment for Relapsed Disease
Speaker: J. Ledermann (United Kingdom)
The Role of Targeted Therapy in Ovarian Cancer
Speaker: S.B. Kaye (United Kingdom)

MONDAY 26 SEPTEMBER 2011
Teaching Lecture: Cancer and Pregnancy: What Should We Know About the Management With Systemic Treatment of Pregnant Women With Cancer?
08:00 - 08:45
Speaker: N. Pavlidis (Greece)

Special Session: Controversies in the Management of Cervical Cancer
13:15 - 14:15
Chair: P. Morice (France)
Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer
Speaker: N. Colombo (Italy)
Image-guided Brachytherapy and External Radiotherapy
Speaker: C. Haie-Méder (France)
Management Aimed at Fertility Preservation
Speaker: F. Amant (Belgium)
Discussion and Roundup

TUESDAY 27 SEPTEMBER 2011
Scientific Symposium: From Bench to Bedside in Ovarian Cancer
09:00 - 11:00
Chair: S.B. Kaye (United Kingdom)
Chair: M. d’Incalci (Italy)
Introduction
Speaker: S.B. Kaye (United Kingdom)

New Concepts on the Origins of Ovarian Cancer
Speaker: J. Prat (Spain)

Genomics of Ovarian Cancer – Utility as Predictive Biomarkers
Speaker: D. Huntsman (Canada)

New Directions in Angiogenesis Therapy
Speaker: G. Jayson (United Kingdom)

Update on Targeted Therapies in Ovarian Cancer
Speaker: C. Sessa (Switzerland)

Concluding Remarks
Speaker: M. d’Incalci (Italy)

Debate: This House Believes That Neoadjuvant Chemotherapy Should Become Standard of Care in Ovarian Cancer
11:30 - 12:30
Moderator: S.B. Kaye (United Kingdom)

Neoadjuvant Chemotherapy Should Become Standard of Care in Ovarian Cancer
Speaker in Favour: I.B. Vergote (Belgium)

Neoadjuvant Chemotherapy Should NOT Become Standard of Care in Ovarian Cancer
Speaker Against: A. du Bois (Germany)

Neoadjuvant Chemotherapy Should Become Standard of Care in Ovarian Cancer
Second in Favour: L. Ungar (Hungary)

Neoadjuvant Chemotherapy Should NOT Become Standard of Care in Ovarian Cancer
Second in Against: P. Morice (France)

Questions and Answers Including Audience and Final Vote to See if Audience Have Changed Their Opinion

HAEMATOLOGICAL MALIGNANCIES AND MYELOMA

Saturday 24 September 2011

Teaching Lecture: Advances in the Treatment of Myeloma
08:00 - 08:45
Speaker: M.A. Dimopoulos (Greece)

Special Session: PET-Based Treatment Decisions in Hodgkin Lymphoma
14:15 - 15:15
Chair: T. Grinsby (France)

FDG-PET in Hodgkin Lymphoma
Speaker: M. Hutchings (Denmark)

PET-Guided Radiation Treatment Planning in Hodgkin Lymphoma
Speaker: T. Grinsby (France)

PET-Response Adapted Therapy in Hodgkin Lymphoma
Speaker: C. Kobe (Germany)

Discussion and Roundup

Scientific Symposium: Role of the Microenvironment in Lymphomas
16:00 - 18:00
Chair: P. Chia (Italy)
Chair: R. Kuppers (Germany)

Introduction
Speaker: R. Kuppers (Germany)

The Microenvironment in B Cell Malignancies: a New Target for Therapy?
Speaker: P. Chia (Italy)

The Stromal Cell Niche in Follicular Lymphoma
Speaker: K. Tarte (France)

Clinical Relevance of the Microenvironment in Hodgkin Lymphoma
Speaker: C. Steidl (Canada)

Impact of the Tumor Microenvironment on Prognosis in Follicular Lymphoma
Speaker: D. de Jong (The Netherlands)

Concluding Remarks
Speaker: P. Chia (Italy)

Sunday 25 September 2011

Teaching Lecture: Diagnostic and Therapeutic Approach of Primary Cutaneous Lymphomas
08:00 - 08:45
Speaker: To Be Announced

Scientific Symposium: Molecular Genetics in Lymphoma - Current Knowledge and New Insights From High-Throughput Technologies
09:00 - 11:00
Chair: B. Coiffier (France)
Chair: V. Ribrag (France)

Introduction
Speaker: B. Coiffier (France)

Chronic Lymphocytic Leukaemia (CLL)
Speaker: T. Zenz (Germany)

Mantle Cell Lymphoma (MCL)
Speaker: B. Coiffier (France)

Diffuse Large Cell Lymphoma (DLCL)
Speaker: A. Rosenwald (Germany)

Follicular Lymphoma
Speaker: J. Fitzgibbon (United Kingdom)

Concluding Remarks
Speaker: V. Ribrag (France)

Monday 26 September 2011

Debate: This House Believes That EPO Should Be Part of Daily Cancer Management
17:00 - 18:00
Moderator: J. Overgaard (Denmark)

EPO Should Be Part of Daily Cancer Management
Speaker in Favour: A. Engert (Germany)

EPO Should NOT Be Part of Daily Cancer Management
Speaker Against: O. Hermine (France)

EPO Should Be Part of Daily Cancer Management
Second in Favour: M. Aapro (Switzerland)

EPO Should NOT Be Part of Daily Cancer Management
Second in Against: M. Dicato (Luxembourg)

Questions and Answers Including Audience and Final Vote to See if Audience Have Changed Their Opinion

HEAD AND NECK CANCER

Saturday 24 September 2011

Teaching Lecture: The Current Treatment of Nasopharyngeal Cancer
08:00 - 08:45
Speaker: A.T. Chan (Hong Kong)

Special Session: Late Toxicity Treatment of Head and Neck Cancer
14:15 - 15:15
Chair: S. Subramanian (Russian Federation)
Biological Insights
Speaker: R. Coppes (The Netherlands)

Late Functional Outcome in Chemo-Radiation
Speaker: H. Langendijk (The Netherlands)

Late Functional Outcome Surgery
Speaker: A. Dietz (Germany)

Discussion and Roundup

Scientific Symposium: Head and Neck: What Next in Biologically Targeted Therapy?
16:00 - 18:00
Chair: K. Harrington (United Kingdom)
Chair: J.B. Vermorken (Belgium)

Introduction
Speaker: J.B. Vermorken (Belgium)

Stem Cells in Head and Neck Cancer
Speaker: D. Zips (Germany)
New Targeted Drugs - Biological Agents  
Speaker: K. Harrington (United Kingdom)  
Management Based on Results of Functional Imaging  
Speaker: K. Newbold (United Kingdom)  
Targeted Agents in Salivary Gland Tumours  
Speaker: L.L. Siu (Canada)  
Concluding Remarks  
Speaker: K. Harrington (United Kingdom)  

SUNDAY 25 SEPTEMBER 2011  
Teaching Lecture: Thyroid – Emerging Tumours  
08:00 - 08:45  
Speaker: M. Schlumberger (France)  
Debate: This House Believes That Patients With HPV+ve Tumours Should Be Managed Differently From Those With HPV-ve Tumours  
13:15 - 14:15  
Moderator: J.B. Vermorken (Belgium)  
Patients With HPV+ve Tumours Should Be Managed Differently From Those With HPV-ve Tumours  
Speaker in Favour: M.L. Gillison (USA)  
Patients With HPV+ve Tumours Should NOT Be Managed Differently From Those With HPV-ve Tumours  
Speaker Against: H. Mehanna (United Kingdom)  
Questions and Answers Including Audience and Final Vote to See If Audience Have Changed Their Opinion  

INDUSTRY TRACK  
SUNDAY 25 SEPTEMBER 2011  
Scientific Symposium: The Role of Medical Technology in Building a Sustainable Cancer Care  
14:45 - 16:45  
How Medical Technologies and Pharmaceutical Industry Can Work Together  
Speaker: To Be Announced  
IT Enabled Clinical Decision Support and Integration of Cancer Care-Role of EMR and Cancer Registries  
Speaker: To Be Announced  
Molecular Diagnostics Role in Personalised Cancer Care  
Speaker: To Be Announced  
The Future of Radiation Therapy in Comprehensive Cancer Care  
Speaker: To Be Announced  

LUNG CANCER- EARLY AND MASTETASTIC  
SATURDAY 24 SEPTEMBER 2011  
Teaching Lecture: Management of Early Non-Small Cell Lung Cancer  
08:00 - 08:45  
Speaker: T. Le Chevalier (France)  
Scientific Symposium: Optimal Treatment for a 72-Year-Old Patient With Stage III-N2 Non-Small Cell Lung Cancer  
16:00 - 18:00  
Chair: D. De Ruyscher (The Netherlands)  
Chair: P.A. Kosmidis (Switzerland)  
Introduction  
Speaker: P.A. Kosmidis (Switzerland)  
Stage III-N2 Non-Small Cell Lung Cancer: Identifying Patients Subgroups and the Need to Tailor Therapy  
Speaker: K. O'Byrne (Ireland)  
Evidence to Support Definitive Chemo-Radiotherapy  
Speaker: D. De Ruyscher (The Netherlands)
Evidence to Support Use of Planned Surgery
Speaker: P. De Leyn (Belgium)

Stage III-N2 Non-Small Cell Lung Cancer: Choice of Chemotherapy Schemes
Speaker: E. Felip Font (Spain)

Concluding Remarks
Speaker: D. De Ruysscher (The Netherlands)

Sunday 25 September 2011
Teaching Lecture: Thymoma
- 08:00 - 08:45
Speaker: P. Baas (The Netherlands)

Special Session: Novel Targeted Therapies for Metastatic Non-Small Cell Lung Cancer
- 15:00 - 16:00
Chair: R. Dziadziuszko (Poland)

ALK Inhibitors
Speaker: D.R. Camidge (USA)

IGF1R Inhibitors
Speaker: L. Paz Ares (Spain)

Other Molecular Targets
Speaker: J.C. Soria (France)

Discussion and Roundup

Monday 26 September 2011
Interactive Session With Patient Cases: Stage IIIa Non-Small Cell Lung Cancer - Views by the Surgeon, Radiotherapist and Medical Oncologist
- 08:00 - 09:00
Chair: G. Giaccone (USA)

Presentation of a Complex Case
Speaker: G. Giaccone (USA)

Surgeon's Point of View
Speaker: U. Pastorino (Italy)

Radiotherapist's Point of View
Speaker: D. Zips (Germany)

Medical Oncologist's Point of View
Speaker: B. Besse (France)

Discussion and Roundup

Scientific Symposium: Non-Small Cell Lung Cancer - Advanced Disease
- 09:00 - 11:00
Chair: C. Faivre-Finn (United Kingdom)

Introduction
Speaker: C. Faivre-Finn (United Kingdom)

The Challenge of Assessing and Targeting Tumour Hypoxia in Non-Small Cell Lung Cancer
Speaker: Q.T. Le (USA)

Intensity Modulated Radiotherapy: Fixed-Beam and Arc Delivery Techniques for Locally Advanced Disease
Speaker: S. Senan (The Netherlands)

Integrating Systemic and Radiation Therapy in Locally Advanced Tumours
Speaker: A. Price (United Kingdom)

Does Surgery Improve Outcome?
Speaker: U. Pastorino (Italy)

Concluding Remarks
Speaker: E. Felip Font (Spain)

Tuesday 27 September 2011
- 09:00 - 11:00
Chair: R. Stahel (Switzerland)

First Line
Speaker: C. Gridelli (Italy)

Second Line
Speaker: F. De Marinis (Italy)

Early Locally Advanced Disease
Speaker: W. Weder (Switzerland)

Small Cell Lung Cancer
Speaker: C. Le Pechoux (France)

Special Session: Treatment of T1-No-M0 Non-Small Cell Lung Cancer in Patients Who Are Not Candidates for Lobectomy
- 11:30 - 12:30
Chair: P. Dartevelle (France)

Alternative Surgical Resections for Lobectomy
Speaker: P. Dartevelle (France)

Role of Stereotactic Radiotherapy
Speaker: M. Guckenberger (Germany)

Role of Radio-Frequency Ablation
Speaker: T. de Baere (France)

Discussion and Roundup

Melanoma and Skin Cancer

Saturday 24 September 2011
Special Session: Too Little or Too Much Surgery for Melanoma
- 14:15 - 15:15
Chair: A. Testori (Italy)

For Sentinel Node Positive Patients: Is Complete Lymph Node Resection Still the Standard?
Speaker: O. Nieweg (The Netherlands)

For Patients With Distant Metastases: Surgery Is First Choice of Treatment
Speaker: S. Schneebaum (Israel)

A Critical View: Selection Is the Standard
Speaker: A.M.M. Eggermont (The Netherlands)

Questions and Answers Including Audience and Final Vote to See if Audience Have Changed Their Opinion

Scientific Symposium: Melanoma - Realising the Potential in Immunotherapy
- 16:00 - 18:00
Chair: A.M.M. Eggermont (The Netherlands)
Chair: L. Zitvogel (France)

Introduction
Speaker: A.M.M. Eggermont (The Netherlands)

Current Insights in Mechanism of Action of Anti-CTLA4
Speaker: J.P. Allison (USA)

Can Chemotherapeutics Synergise With Anti-CTLA4?
Speaker: L. Zitvogel (France)

Update Anti-CTLA in First Line and Second Line Therapy
Speaker: J. Wolchok (USA)

Combination Strategies
Speaker: J.S. Weber (USA)

Concluding Remarks
Speaker: L. Zitvogel (France)

Sunday 25 September 2011
Teaching Lecture: Current Approaches to Adjuvant Therapy of Melanoma
- 08:00 - 08:45
Speaker: S. Aamdal (Norway)

Scientific Symposium: Melanoma Therapy - Realising the Potential in Targeted Therapy
- 09:00 - 11:00
Chair: R. Marais (United Kingdom)
Chair: C. Robert (France)
ONCOLOGY MARAIS

Saturday 24 September 2011

Opening Session: Oncology Nursing Opening and Award Session 1:00 - 1:15

EONS Distinguished Merit Award Speaker: To Be Announced

Scientific Symposium: Telethinking in Cancer Care 1:15 - 1:30

Chair: N. Kearney (United Kingdom)
Chair: Y. Wengström (Sweden)

Introduction Speaker: D. Benton (Switzerland)

Technologies and Challenges for Nurses and Health Care
Speaker: D. Benton (Switzerland)

Patient-Centred Technologies - the Future Is Here
Speaker: N. Kearney (United Kingdom)

Using Technology in Palliative Care - a Reality
Speaker: B. Johnston (United Kingdom)

Introduction of the ‘Health Buddy’ Into Patient Homes to Help Patients Who Are Receiving Palliative Chemotherapy
Speaker: J. Korsten (The Netherlands)

Concluding Remarks Speaker: N. Kearney (United Kingdom)

Special Session: Developments in Surgical Oncology 1:45 - 1:55

Chair: M. Wells (United Kingdom)

Improving the Diagnostic Pathway for Men With Prostate Cancer
Speaker: M. Emberton (United Kingdom)

Robotics - Opportunities and Issues for Nursing
Speaker: S. Martin (United Kingdom)

Health-Related Quality of Life as a Prognostic Factor in Patients With Oesophageal Cancer
Speaker: G. Lagergren (Sweden)

Discussion and Roundup

Special Session: Adolescent and Young Adult Cancer Patients: Are We Meeting Their Needs? 14:15 - 15:15

Chair: D. Kelly (United Kingdom)

Why Are Adolescents Diagnosed Later With Cancer?
Speaker: F. Gibson (United Kingdom)

Life Five Years Beyond Diagnosis
Speaker: L. Wettergren (Sweden)

Keeping Their World Together - Network-Focused Nursing in Teenager and Young Adult Cancer Care
Speaker: P. Olsen (Denmark)

Discussion and Roundup

Scientific Symposium: Probiotics, Calories and Cancer Care 16:00 - 18:00

Chair: S. Kau (Turkey)
Chair: U. Östlund (Sweden)

Introduction Speaker: S. Kau (Turkey)

Probiotics and Colon Cancer Prevention
Speaker: J. Rafter (Sweden)

Assessment and Management of Gastrointestinal Symptoms After Cancer Treatments
Speaker: J. Andreyev (United Kingdom)

Confinement Interventions - Bowel Problems
Speaker: C. Taylor (United Kingdom)

The Experience of Living With a PEG
Speaker: U. Östlund (Sweden)

Concluding Remarks Speaker: U. Östlund (Sweden)

Sunday 25 September 2011

Teaching Lecture: Introduction to Lung Cancer Curriculum (Part 1): Basic Science of Lung Cancer 08:00 - 08:45

Speaker: H. Kristeleit (United Kingdom)

Scientific Symposium: Symptom Management 09:00 - 11:00

Chair: A. Molassiotis (United Kingdom)
Chair: P. Dielenseger (France)
Monday 26 September 2011

Teaching Lecture: Introduction to Lung Cancer Curriculum (Part 2): Epidemiology of Lung Cancer

08:00 - 08:45
Speaker: S.J. O’Connor (The Netherlands)

Scientific Symposium: Survivorship and Life Style Changes After Cancer (Diagnosis)

09:00 - 11:00
Chair: L. Sharp (Sweden)
Chair: S. Faithfull (United Kingdom)

Introduction
Speaker: L. Sharp (Sweden)

Breast Cancer and Return to Work
Speaker: K. Alexanderson (Sweden)

Addressing Consequences of Treatment: the Role of Rehabilitation
Speaker: K. Robb (United Kingdom)

The Role of Positive Psychology in Cancer Care
Speaker: K. Bränström (Sweden)

Cancer as a Teachable Moment
Speaker: B. Byrne (United Kingdom)

Concluding Remarks
Speaker: S. Faithfull (United Kingdom)

Special Session: Developments and Management of Lymphoedema

13:15 - 14:15
Chair: M. Sneddon (United Kingdom)

The Extent of the Problem Over Time
Speaker: M. Sneddon (United Kingdom)

Management Options
Speaker: J. Simmons (United Kingdom)

The Management of Lymphoedema in Advanced Cancer
Speaker: A. Honnor (United Kingdom)

Discussion and Roundup

Special Session: Optimal Care in Rare Cancers

13:15 - 14:15
Chair: L. Sharp (Sweden)

Palliative Care Issues in Patients With Brain Tumours
Speaker: C. Ostgathe (Germany)

Kidney Cancers
Speaker: E. Gustafsson (Sweden)

Head and Neck Cancer
Speaker: S. Kagan (USA)

Discussion and Roundup

Scientific Symposium: Nursing Science

14:45 - 16:45
Chair: Y. Wengström (Sweden)
Chair: D. Kelly (United Kingdom)

Introduction
Speaker: Y. Wengström (Sweden)

Patient-Centred Care - Building Capacity for Research and Clinical Care
Speaker: I. Ekman (Sweden)

Advanced Cancer Patients as Participants in Their Own Lives - a Qualitative Study of Coping From a Patient Perspective
Speaker: T.G. Thomsen (Denmark)

An Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation Therapy - a Clinical Controlled Randomised Trial
Speaker: M. Jarden (Denmark)

Towards Defining and Measuring the Fundamentals of Care
Speaker: A. Kitson (Australia)

Concluding Remarks
Speaker: D. Kelly (United Kingdom)

Debate: This House Believes That Alternative Therapies Have a Place in Cancer Care

17:00 - 18:00
Moderator: C. Tishelman (Sweden)

Alternative Therapies Have a Place in Cancer Care
Speaker Against: G. Eckerdal (Sweden)

Alternative Therapies Do NOT Have a Place in Cancer Care
Speaker in Favour: A. Molassiotis (United Kingdom)

Alternative Therapies Do NOT Have a Place in Cancer Care
Second in Favour: T. Falkenberg (Sweden)

Alternative Therapies Have a Place in Cancer Care
Second Against: C. Wylegalla (Germany)

Questions and Answers Including Audience and Final Vote to See if Audience Have Changed Their Opinion

Interactive Workshop: Dealing With Emotionally Challenging Patients or Families

17:00 - 18:00
Coordinator: L. Fallowfield (United Kingdom)

Tuesday 27 September 2011

Teaching Lecture: Introduction to Lung Cancer Curriculum (Part 3): Chemotherapy in Lung Cancer

08:00 - 08:45
Speaker: R. Lal (United Kingdom)

Scientific Symposium: Transitions in Care for Cancer Patients

09:00 - 11:00
Chair: M. Brouwali (Sweden)
Chair: B. Grube (Denmark)

Introduction
Speaker: B. Grube (Denmark)

Ambulatory Care
Speaker: K. White (Australia)

Cultural Aspects in the Transition From Hospital to Community Care
Speaker: E. Shadmi (Israel)

Transition to Survivorship: Key Issues and Models of Care
Speaker: M.S. McCabe (USA)

Concluding Remarks
Speaker: M. Browall (Sweden)

Special Session: End of Life Care in Oncology

11:30 - 12:30
Chair: P. Fernandez-Ortega (Spain)

Recognising Dying and End-of-Life Prognostication in Elderly Cancer Patients
Speaker: S.J. O’Connor (Belgium)

Dying Well - Challenges in Acute Oncology Settings
Speaker: P. Larkin (Ireland)

Nurses Attitudes Towards Caring for Dying Patients in Acute Settings
Speaker: M. Arantzamendi Solabarrieta (Spain)

12:00 Discussion and Roundup

Oncopoly

Monday 26 September 2011

Oncopoly Forum Session: Inequalities in Clinical Trials

09:00 - 11:00
Session: To Be Announced

Oncopoly Forum Session: Optimising Access to Cancer Drugs in Europe

13:15 - 14:15
Session: To Be Announced

Oncopoly Forum Session: Inequalities in Research

14:45 - 16:45
Session: To Be Announced

Oncopoly Forum Session: European Partnership for Action Against Cancer

17:00 - 18:00
Session: To Be Announced
Tuesday 27 September 2011

Oncopoly Forum Session: Inequalities in Access to Drugs and Quality of Care
- 09:45 - 11:30
Session: To Be Announced

Onco-Technology

Saturday 24 September 2011

Scientific Symposium: Nanotechnologies for Targeted Drug Delivery
- 11:15 - 13:15
Chair: G. Storm (The Netherlands)
Chair: R. Aebersold (USA)
Introduction
Speaker: G. Storm (The Netherlands)
Nanoplatforms for Targeted Macromolecular Delivery
Speaker: M.J. Alonso (Spain)

Nanocarrier Pharmacokinetics and Pharmacodynamics: Watching Where Nanoparticles go
Speaker: K. Kostarelis (United Kingdom)

Pharmacokinetics and Pharmacodynamics of Drug Nanocarriers
Speaker: To Be Announced

Temperature Sensitive Drug Nanocarriers
Speaker: H. Gruell (The Netherlands)

Polymeric Nanoparticles and Drug Targeting
Speaker: R. Aebersold (USA)

Concluding Remarks
Speaker: R. Aebersold (USA)

Scientific Symposium: New Image Guided Cancer Therapies
- 16:00 - 18:00
Chair: C. Moonen (France)
Chair: D. Verellen (Belgium)
Introduction
C. Moonen (France)

Application of MRI for Radiotherapy Dose Painting
Speaker: U. Van der Heide (The Netherlands)

Fluorescence Guided Cancer Therapy
Speaker: P.K. Selbo (Norway)

MRI Guided Focused Ultrasound in Brain
Speaker: To Be Announced

MRI Guided Focused Ultrasound Applications in the Body
Speaker: F. Busse (Finland)

Image Guidance for Temperature Sensitive Nanoparticle Drug Carriers
Speaker: To Be Announced

Concluding Remarks
Speaker: D. Verellen (Belgium)

Sunday 25 September 2011

Scientific Symposium: Novel Oncoproteomic Technology
- 09:00 - 11:00
Chair: R. Aebersold (USA)
Chair: G. Pestlin (USA)
Introduction
Speaker: G. Pestlin (USA)

Proteomics and Personalised Medicine - Array Based Technologies
Speaker: C. Jimenez (The Netherlands)

Mass Spectrometry-Based Proteomics
Speaker: To Be Announced

Tissue Proteomics and the Molecular Phenotype
Speaker: J. Celis (Denmark)

Protein Kinase Activity and Therapy Response
Speaker: K. Kostarelis (United Kingdom)

Cancer Protein Biomarkers
Speaker: R. Aebersold (USA)

Concluding Remarks
Speaker: R. Aebersold (USA)

Special Session: Assessment of Novel Oncotechnologies
- 13:15 - 14:15
Chair: D.R. Olsen (Norway)

Assessment of Novel Oncotechnologies
Speaker: To Be Announced

Randomised Clinical Trials in Assessment of Oncotechnologies
Speaker: S.M. Bentzen (USA)

Industry Perspective on Assessment of Oncotechnologies
Speaker: To Be Announced

Discussion and Roundup

Monday 26 September 2011

Scientific Symposium: Novel Radiation Technologies and Strategies
- 09:00 - 11:00
Chair: W. Enghardt (Germany)
Chair: A. Lomax (Switzerland)
Introduction
Speaker: W. Enghardt (Germany)

Adaptive Radiation Therapy - Technology and Strategies
Speaker: To Be Announced

Integrated MRI-Guided Advanced Radiotherapy
Speaker: J. Lagendijk (the Netherlands)

Scanned Intensity-Modulated proton Therapy
Speaker: A. Lomax (Switzerland)

Laser-Accelerated Proton Therapy
Speaker: W. Enghardt (Germany)

Concluding Remarks
Speaker: A. Lomax (Switzerland)

Paediatric Oncology

Saturday 24 September 2011

Long Term Follow Up in Childhood and Adolescent Cancer
- 11:15 - 13:15
Chair: K. Røe (Norway)
Chair: G. Storm (The Netherlands)

Pan-European Network for Care of Survivors After Childhood and Adolescent Cancer (PanCare)
Speaker: L.J. Hjorth (Sweden)

The Epidemiology of Childhood Cancer Survivors
Speaker: R. Haupt (Italy)

Transition From Paediatric to Adult Care - Models of Care
Speaker: E. Frey (Austria)

Late Complications After Cancer in Childhood and Adolescence
Speaker: G. Levitt (United Kingdom)

ICCCPO (the International Confederation of Childhood Cancer Parent Organisations) – the Survivors Perspectives
Speaker: A. Kienesberger (Austria)

Concluding Remarks
Speaker: L.J. Hjorth (Sweden)

Scientific Symposium: Research Strategy of the Paediatric and Adolescents European Tumour Groups
- 16:00 - 18:00
Chair: M. Schrappe (Germany)
Chair: A. Biondi (Italy)
Introduction
Speaker: M. Schrappe (Germany)

Soft-Tissue Sarcomas
Speaker: J. Chisholm (United Kingdom)

High Risk Neuroblastoma
Speaker: R. Ladenstein (Austria)

Non Hodgkin Lymphomas
Speaker: C. Patte (France)

Relapsed Acute Lymphoblastic Leukemias
Speaker: M. Schrappe (Germany)

Very Rare Cancers in Children
Speaker: G. Bisogno (Italy)

Concluding Remarks
Speaker: A. Biondi (Italy)
Sunday 25 September 2011

Teaching Lecture: Medulloblastoma
08:00 - 08:45
Speaker: I. Padovani (France)

Special Session: The European Network for Cancer Research in Children and Adolescents (ENCCA) FP7 Project
13:15 - 14:15
Chair: R. Riccardi (Italy)
European Network for Cancer Research in Children and Adolescents an FP7 Project (ENCCA)
Speaker: R. Ladenstein (Austria)
Integrating Activities of ENCCA
Speaker: K. Fitckhard-Jones (United Kingdom)
Joint Research Activities of ENCCA
Speaker: M. Schrappe (Germany)
Spread of Excellence Activities of ENCCA
Speaker: G. Vassal (France)
Discussion and Roundup

Scientific Symposium: Brain Tumours in Children and Adolescents
14:45 - 16:45
Chair: D. Walker (United Kingdom)
Introduction
Speaker: D. Walker (United Kingdom)
Are Adult and Paediatric High Grade Gliomas the Same - Insight From Biology and Molecular Pathology
Speaker: J. Grill (France)
The EU Research Strategy for High Grade Glioma in Children and Adolescents - Can We Extrapolate From Adult Data?
Speaker: D. Hargrave (United Kingdom)
Molecular Characterisation of Medulloblastoma - the Route Towards Personalised Care
Speaker: T. Pietsch (Germany)
Functional Imaging in Adult and Paediatric Brain Tumours
Speaker: A.C. Peet (United Kingdom)
Concluding Remarks
Speaker: I. Slavc (Austria)

Monday 26 September 2011

Teaching Lecture: Ewing Sarcoma Treatment
08:00 - 08:45
Speaker: H.F. Jürgens (Germany)

Scientific Symposium: The Role of IGFs/IGF-1R Pathway in Paediatric Malignancies
09:00 - 11:00
Chair: B.J. Morland (United Kingdom)
Chair: J. Ricort (France)

Introduction
Speaker: J. Ricort (France)

Biology of IGF/IGFR Pathway in Ewing and Soft Tissue Sarcomas
Speaker: H. Kovar (Austria)
IGF1R Inhibitors in the Treatment of Ewing Sarcomas
Speaker: J. Helman (USA)
IGF1R Targeting in Non-Sarcoma Pediatric Malignancies
Speaker: B. Geoerger (France)
The IGF1's Growth Hormone Axis in Human Development
Speaker: J. Ricort (France)

Concluding Remarks
Speaker: B.J. Morland (United Kingdom)

Debate: This House Believes That Proton Therapy in Paediatric Oncology Improves Clinical Outcome
13:15 - 14:15
Moderator: B.L. Pizer (United Kingdom)
Proton Therapy in Paediatric Oncology Improves Clinical Outcome
Speaker in Favour: B. Timmermann (Switzerland)
Proton Therapy in Paediatric Oncology Does NOT Improve Clinical Outcome
Speaker Against: J.M. Michalski (USA)
Proton Therapy in Paediatric Oncology Improves Clinical Outcome
Secconder in Favour: J.L. Habrand (France)
Proton Therapy in Paediatric Oncology Does NOT Improve Clinical Outcome
Secconder Against: E. Halperin (USA)
Questions and Answers Including Audience and Final Vote to See if Audience Have Changed Their Opinion

Scientific Symposium: Drug Development in Paediatric Oncology
14:45 - 16:45
Chair: G. Vassal (France)
Chair: B.J. Morland (United Kingdom)
Introduction
Speaker: B.J. Morland (United Kingdom)

4 Years Later - the Impact of the European Pediatric Medicine Regulation on Children and Adolescents in Europe
Speaker: G. Vassal (France)
PARP Inhibition in Pediatric Malignancies
Speaker: A. Pearson (United Kingdom)
Targeting ALK in Paediatric Malignancies
Speaker: T. Pietsch (France)
Immunotherapy of Paediatric Malignancies
Speaker: V. Minard-Colin (France)

Apoptosis Research in Paediatric Malignancies - New Targets for Therapy
Speaker: S. Fulda (Germany)
Concluding Remarks
Speaker: G. Vassal (France)

Patient Advocacy / Ethics

Saturday 24 September 2011

Advocacy and Ethics Session: Getting Personal - Treatment in the Age of Targeted Therapies
11:15 - 13:15
Co-Chair: S. Kyriahdes (Cyprus)
Co-Chair: F. Cardoso (Portugal)
Personalised Medicine: Would it Work for Me?
Speaker: R. Wilson (United Kingdom)
Treating the Patient, Not Just The Disease
Speaker: A. Novik (Russia)
Challenges on the Road to Drug Approval
Speaker: F. Pignatti (United Kingdom)
Targeted Therapies: At What Cost?
Speaker To Be Announced
Personalised Medicine - Can Industry Deliver?
Speaker: G. Guidi (Italy)

Court Room Trial: Patient Information on Trial
14:15 - 15:15
Judge: J. Bousis (United Kingdom)
Prosecutor: I. Banks (United Kingdom)
Defendant: Patient Information
Expert Witnesses:
L. Fallousfield (United Kingdom)
K. Konstanty (Poland)
E. Bergsten-Nordstrom (Sweden)
I. Passarini (Belgium)
Jury/Audience to Vote Guilty or Not Guilty

Advocacy and Ethics Session: The Challenges of Rare Cancers
16:00 - 18:00
Co-Chair: K. Oliver (United Kingdom)
Co-Chair: R. Schafer (Germany)
2.7 Million Reasons Why We Need to Improve the Rare Cancer Journey
Speaker: K. Oliver (United Kingdom)
Rarity and Research– Challenges for the International Cancer Community
Speaker: J.Y. Blay (France)
Rare Cancer Advocacy Groups and the EMA - Creating a Sustainable Partnership
Speaker: K. Westermark (Sweden)
### Sunday 25 September 2011

#### Advocacy and Ethics Session: Cancer at Any Age - Ethics and Challenges
- **09:00 - 11:00**
  - **Co-Chair:** T. Hudson (Ireland)
  - **Co-Chair:** L. Jost (Switzerland)

**Ethical Learnings from Paediatric Cancer Research**
- **Speaker:** D. Walker (United Kingdom)

**Ethical Dilemmas in the Management of Teenage Cancer Patients**
- **Speaker:** F. Gibson (United Kingdom)

**To Enrol or Not to Enrol - Ethical Considerations for Clinical Trial Participation**
- **Speaker:** N. Stingelin (Switzerland)

**Too Old to Be Treated?**
- **Speaker:** M. Aapro (Switzerland)

**Palliative Care: More Than Just End of Life Treatment**
- **Speaker:** N. Cherny (Israel)

### Advocacy and Ethics Session: Cancer and the Internet
- **13:15 - 14:15**
  - **Chair:** J. Geissler (Germany)

**Eurocancercoms: Cancer Superportal**
- **Speaker:** R. Sullivan (United Kingdom)

**Serving Patient Communities Through Social Media**
- **Speaker:** D. Costello (France)

**Running Sustainable Online Communities**
- **Speaker:** G. Frydman (United States of America)

### Advocacy and Ethics Session: Cancer Research - Ethics and Challenges
- **14:45 - 16:45**
  - **Co-Chair:** I. Kössler (Sweden)
  - **Co-Chair:** N. Wilking (Sweden)

**Clinical trials - Are Patients 'Lost in Translation'?**
- **Speaker:** P. Garcia-Prieto (Belgium)

**Ethics in Cancer Biobanking**
- **Speaker:** K. Zatloukal (Austria)

**Patient Advocates and Ethical Review Boards**
- **Speaker:** P. Knupffer (Germany)

**Should ALL Trial Results - Good and Bad - be Published and Made Publicly Available?**
- **Speaker:** U. Ringborg (Sweden)

**Conventional Medicine and CAM - a Happy Partnership?**
- **Speaker:** H. Jernström (Sweden)

### Sunday 25 September 2011

#### Advocacy and Ethics Session: Cancer at Any Age - Ethics and Challenges
- **09:00 - 11:00**
  - **Co-Chair:** T. Hudson (Ireland)
  - **Co-Chair:** L. Jost (Switzerland)

**Ethical Learnings from Paediatric Cancer Research**
- **Speaker:** D. Walker (United Kingdom)

**Ethical Dilemmas in the Management of Teenage Cancer Patients**
- **Speaker:** F. Gibson (United Kingdom)

**To Enrol or Not to Enrol - Ethical Considerations for Clinical Trial Participation**
- **Speaker:** N. Stingelin (Switzerland)

**Too Old to Be Treated?**
- **Speaker:** M. Aapro (Switzerland)

**Palliative Care: More Than Just End of Life Treatment**
- **Speaker:** N. Cherny (Israel)

### Advocacy and Ethics Session: Cancer and the Internet
- **13:15 - 14:15**
  - **Chair:** J. Geissler (Germany)

**Eurocancercoms: Cancer Superportal**
- **Speaker:** R. Sullivan (United Kingdom)

**Serving Patient Communities Through Social Media**
- **Speaker:** D. Costello (France)

**Running Sustainable Online Communities**
- **Speaker:** G. Frydman (United States of America)

### Advocacy and Ethics Session: Cancer Research - Ethics and Challenges
- **14:45 - 16:45**
  - **Co-Chair:** I. Kössler (Sweden)
  - **Co-Chair:** N. Wilking (Sweden)

**Clinical trials - Are Patients 'Lost in Translation'?**
- **Speaker:** P. Garcia-Prieto (Belgium)

**Ethics in Cancer Biobanking**
- **Speaker:** K. Zatloukal (Austria)

**Patient Advocates and Ethical Review Boards**
- **Speaker:** P. Knupffer (Germany)

**Should ALL Trial Results - Good and Bad - be Published and Made Publicly Available?**
- **Speaker:** U. Ringborg (Sweden)

**Conventional Medicine and CAM - a Happy Partnership?**
- **Speaker:** H. Jernström (Sweden)
Adaptive Radiotherapy Does NOT Reduce Side Effects and Allows Treatment Intensification
Seconded Against: V. Budach (Germany)

Questions and Answers Including Audience and Final Vote to See if Audience Have Changed Their Opinion

Monday 26 September 2011

Teaching Lecture: Radiation Therapy and Radioisotopes for Bone Metastases: What Is Their Real Benefit?
- 08:00 - 08:45
  Speaker: U. Nestle (Germany)

Special Session: Advanced Technology for Radiotherapy
- 13:15 - 14:15
  Chair: E.B. Hug (Switzerland)

Clinical Experience With Carbon Ion Radiotherapy
Speaker: J. Debus (Germany)

Protons for Radiotherapy of Lung Cancer
Speaker: M. Stuschke (Germany)

Advanced Photon Therapy
Speaker: D. Verellen (Belgium)

Discussion and Roundup

Tuesday 27 September 2011

Teaching Lecture: Combining Molecular Targeted Agents and Radiotherapy
- 08:00 - 08:45
  Speaker: T. Brunner (United Kingdom)

Scientific Symposium: Partial Breast Irradiation
- 09:00 - 11:00
  Chair: J.R. Yarnold (United Kingdom)
  Chair: P. Poortmans (The Netherlands)

Introduction
Speaker: J.R. Yarnold (United Kingdom)

Clinical Radiobiology of Partial Breast Irradiation
Speaker: C. Petersen (Germany)

Partial Breast Irradiation With External Beam Radiotherapy
Speaker: R. Orecchia (Italy)

Brachytherapy for Partial Breast Irradiation
Speaker: E. Van Limbergen (Belgium)

Summary: Concept, Rationale, Evidence and Future Directions
Speaker: J.R. Yarnold (United Kingdom)

Concluding Remarks
Speaker: P. Poortmans (The Netherlands)

Special Session: Stereotactic Radiotherapy for Liver Metastases
- 11:30 - 12:30
  Chair: E. Lartigau (France)

Radiobiological Aspects of Radiation-Induced-Liver-Disease
Speaker: H. Christiansen (Germany)

Clinical Results
Speaker: L.A. Dawson (Canada)

Technical Requirements and Quality Assurance
Speaker: T. Brunner (United Kingdom)

Discussion and Roundup

Thursday 29 September 2011

Clinical Experience With Carbon Ion Radiotherapy
Speaker: J. Debus (Germany)

Protons for Radiotherapy of Lung Cancer
Speaker: M. Stuschke (Germany)

Advanced Photon Therapy
Speaker: D. Verellen (Belgium)

Discussion and Roundup

Sunday 25 September 2011

Scientific Symposium: The Application of Pharmacometrics in Oncology
- 09:00 - 11:00
  Chair: P. Hartvig (Denmark)
  Chair: A. Astier (France)

Introduction
Speaker: P. Hartvig (Denmark)

Application of Population PK-PD Methods in Oncology
Speaker: E. Chatelut (France)

Considerations in PK-PD of Antibodies
Speaker: C. Kroft (Germany)

Pharmacometrics to Improve Treatment of Cancer in Children
Speaker: A. Huijema (The Netherlands)

Optimising Phase I Trials With Modelling and Simulation using Pharmacometrics
Speaker: I. Trocóniz (Spain)

Concluding Remarks
Speaker: A. Astier (France)

Special Session: Cross-Over in Trials
- 13:15 - 14:15
  Chair: I.F. Tannock (Canada)

Early Approval Versus Late Approval
Speaker: F. Pignatti (United Kingdom)

What Are the Current Thoughts on Cross-Over Designs?
Speaker: D. Sargent (USA)

Cross-Over - the Clinician's Perspective
Speaker: I.F. Tannock (Canada)

Discussion and Roundup

Debate: This House Believes That Prospective Randomised Trials Should Be Stopped if At Interim Analysis a Sufficient Positive Effect Can Be Detected
- 15:00 - 16:00
  Moderator: D. Lacombe (Belgium)

Prospective Randomised Trials Should Be Stopped if At Interim Analysis a Sufficient Positive Effect Can Be Detected
Speaker in Favoure: P.E. Goss (USA)

Prospective Randomised Trials Should NOT Be Stopped if At Interim Analysis a Sufficient Positive Effect Can Be Detected
Speaker Against: J. Bogaerts (Belgium)

Prospective Randomised Trials Should Be Stopped if At Interim Analysis a Sufficient Positive Effect Can Be Detected
Speaker Against: C. Dittrich (Austria)

Questions and Answers Including Audience and Final Vote to See if Audience Have Changed Their Opinion
SARCOMA: SOFT TISSUE AND BONE

MONDAY 26 SEPTEMBER 2011

Special Session: Management of Retroperitoneal Sarcoma
- 13:15 - 14:15
  Chair: S. Bonvalot (France)
  Differential Diagnosis of Retroperitoneal Sarcoma
  Speaker: P.C.W. Hogendoorn (The Netherlands)
  Surgical Management of Primary Retroperitoneal Sarcomas:
  Improving Outcomes
  Speaker: D. Strauss (United Kingdom)
  The Role of Radiotherapy in Retroperitoneal Sarcoma
  Speaker: F. Quenet (France)

Discussion and Roundup

Scientific Symposium: New Avenues in Soft Tissue Sarcoma
- 14:45 - 16:45
  Chair: P. Schöffski (Belgium)
  Chair: K. Sundby Hall (Norway)
  Introduction
  Speaker: P. Schöffski (Belgium)
  Inappropriate Initial Approaches to Soft Tissue Sarcoma (Clinical, Biopsy, Surgery, Imaging)
  Speaker: A. Hayes (United Kingdom)
  Soft Tissue Sarcoma as a Role Model for Targeted Treatment and Drug Development
  Speaker: J.Y. Blay (France)
  Innovative Radiotherapy Approaches in Soft Tissue Sarcoma
  Speaker: P. Scalliet (Belgium)
  Who Needs a (New) Histopathological and/or Molecular Classification?
  Speaker: A.P. Dei Tos (Italy)
  Concluding Remarks
  Speaker: K. Sundby Hall (Norway)

Debate: This House Believes That Preoperative Chemotherapy is Not Yet Standard of Care in Soft Tissue Sarcoma
- 17:00 - 18:00
  Moderator: F. Van Coevorden (The Netherlands)

Preoperative Chemotherapy is NOT Yet Standard of Care in Soft Tissue Sarcoma
  Speaker in Favour: I. Judson (United Kingdom)
  Speaker Against: A. Le Cesne (France)

Questions and Answers Including Audience and Final Vote to See if Audience Have Changed Their Opinion

TUESDAY 27 SEPTEMBER 2011

Teaching Lecture: Soft Tissue Sarcomas: Are All Soft Tissue Sarcomas Treated With the Same Drugs?
- 08:00 - 08:45
  Speaker: J.Y. Blay (France)

Special Session: Desmoid Fibromatosis Tumours Representing an Unmet Medical Need
- 11:30 - 12:30
  Chair: P. Hohenberger (Germany)
  How Much Surgery and When?
  Speaker: A. Gronchi (Italy)
  Radiotherapy as Adjuvant Treatment to Surgery or as Definitive Treatment?
  Speaker: V. Budach (Germany)
  Systemic Treatments for Desmoids Fibromatosis
  Speaker: I. Judson (United Kingdom)

Discussion and Roundup

SURGICAL ONCOLOGY

SATURDAY 24 SEPTEMBER 2011

Special Session: Peritoneal Surface Oncology - the Evidence for Locoregional Treatment
- 14:15 - 15:15
  Chair: S. Gonzalez-Moreno (Spain)
  Peritoneal Carcinomatosis of Colorectal Origin
  Speaker: F. Quenet (France)
  Peritoneal Mesothelioma
  Speaker: M. Deraco (Italy)
  Pseudomyxoma Peritonei
  Speaker: S. Gonzalez-Moreno (Spain)

Discussion and Roundup

Debate: This House Believes That Preoperative Chemotherapy is Not Yet Standard of Care in Soft Tissue Sarcoma

Sunday 25 September 2011

Special Session: Esophageal Cancer - Ways to Improve Outcome
- 13:15 - 14:15
  Chair: T. Lehnert (Germany)
  How Radical Should Surgery Be?
  Speaker: C. Mariette (France)

Discussion and Roundup

MONDAY 26 SEPTEMBER 2011

Teaching Lecture: Skin-Sparing Mastectomy
- 08:00 - 08:45
  Speaker: A.D. Baildam (United Kingdom)

Scientific Symposium: Contributors to Better Survival in Colorectal Cancer
- 14:45 - 16:45
  Chair: C.J.H. van de Velde (The Netherlands)
  Introduction
  Speaker: A.F. Sobrero (Italy)
  The Contribution of Evidence Based Guidelines and Compliance to Colon Cancer Survival
  Speaker: G. Poston (United Kingdom)
  Better Staging Leads to Better Survival in Colon Cancer; the Sentinel Node Reappraised
  Speaker: M. Zuber (Switzerland)
  Neoadjuvant Treatment in Colon Cancer
  Speaker: A.F. Sobrero (Italy)
  The Role of Radiotherapy for Better Survival in Rectal Cancer
  Speaker: C. Rödel (Germany)
  Making Non-Resectable Colorectal Cancer Resectable
  Speaker: W. Hohenberger (Germany)
  Concluding Remarks
  Speaker: C.J.H. van de Velde (The Netherlands)

TUESDAY 27 SEPTEMBER 2011

Teaching Lecture: Overview on the Role of Laparoscopic Surgery in Cancer Management
- 08:00 - 08:45
  Speaker: P. Willemsen (Belgium)

Special Session: Surgical Treatment in Breast Cancer Patients With Distant Metastases
- 11:30 - 12:30
  Chair: M. Leidenius (Finland)
  Surgery of the Primary Tumour
  Speaker: G. Vlastos (Switzerland)
  Surgery of Liver and Pulmonary Metastases
  Speaker: R. Adam (France)

Discussion and Roundup

Will Centralisation Improve Outcome?
  Speaker: R.C. Mason (United Kingdom)

Neoadjuvant Treatment – Better than Surgery Alone?
  Speaker: T. Lehnert (Germany)

Making Non-Resectable Colorectal Cancer Resectable
  Speaker: W. Hohenberger (Germany)

Better Staging Leads to Better Survival in Colon Cancer; the Sentinel Node Reappraised
  Speaker: M. Zuber (Switzerland)

Guidelines and Compliance to Colon Cancer Survival
  Speaker: G. Poston (United Kingdom)

Better Survival in Colorectal Cancer
  Speaker: C. Rödel (Germany)

CONCLUDING REMARKS

The Contribution of Evidence Based Guidelines and Compliance to Colon Cancer Survival
  Speaker: G. Poston (United Kingdom)

Better Staging Leads to Better Survival in Colon Cancer; the Sentinel Node Reappraised
  Speaker: M. Zuber (Switzerland)

Neoadjuvant Treatment in Colon Cancer
  Speaker: A.F. Sobrero (Italy)

The Role of Radiotherapy for Better Survival in Rectal Cancer
  Speaker: C. Rödel (Germany)

Making Non-Resectable Colorectal Cancer Resectable
  Speaker: W. Hohenberger (Germany)

Concluding Remarks
  Speaker: C.J.H. van de Velde (The Netherlands)
SYMPOM SCIENCE

SUNDAY 25 SEPTEMBER 2011

Scientific Symposium: Improved Pain Control Through a Collaborative Approach Between Oncology, Pain and Palliative Care Specialists

14:45 - 16:45
Chair: S. Kaasa (Norway)
Chair: D. Büche (Switzerland)

Introduction
Speaker: D. Büche (Switzerland)

How to Improve Cancer Pain Control Through European Guidelines for Opioid Treatment and Cancer Pain Diagnosis
Speaker: S. Kaasa (Norway)

What is the Place of and Effect of Chemotherapy Including Modern Targeted Therapies to Prevent and to Treat Cancer Pain
Speaker: N.I. Cherny (Israel)

What is the Place for an Effect of Surgery to Prevent and/or to Treat Cancer Pain
Speaker: B. Axelsson (Sweden)

What is the Place and Effect of Radiotherapy and What is the Optimal Schedule for Cancer Pain
Speaker: P. Hoskin (United Kingdom)

A Future Research Agenda to Improve Pain Control Through Collaborative Efforts
Speaker: D. Büche (Switzerland)

Concluding Remarks
Speaker: S. Kaasa (Norway)

MONDAY 26 SEPTEMBER 2011

Teaching Lecture: Emergency and Palliative Care
08:00 - 08:45
Speaker: D. Schrijvers (Belgium)

Scientific Symposium: Treatment of Dyspnea - What Does the Evidence Support?
14:45 - 16:45
Chair: S. Börjeson (Sweden)
Chair: N.I. Cherry (Israel)

Introduction
Speaker: S. Börjeson (Sweden)

Inhaled Furosemide - Yes or No?
Speaker: S. Booth (United Kingdom)

Opioids
Speaker: I. Ben Aharon (Israel)

Benzodiazepines
Speaker: S.T. Simon (United Kingdom)

Pleural Effusion Management
Speaker: P. Girard (France)

Concluding Remarks
Speaker: N.I. Cherry (Israel)

TRANSLATIONAL RESEARCH

SATURDAY 24 SEPTEMBER 2011

Special Session: Immunotherapy - the Future
14:15 - 15:15
Chair: To Be Announced

Immunotherapy
Speaker: L. Zitvogel (France)

DNA Vaccination
Speaker: J.B.A.G. Haanen (The Netherlands)

Combined Radiotherapy and Immunoradiotherapy
Speaker: J. Hodge (USA)

Discussion and Roundup

TUESDAY 27 SEPTEMBER 2011

Scientific Symposium: Relieving Symptoms of Hormonal Therapies in Patients With Breast Cancer
09:00 - 11:00
Chair: M. Aapro (Switzerland)
Chair: Y. Wengström (Sweden)

Introduction
Speaker: M. Aapro (Switzerland)

Endocrine Symptom Assessment in Women With Breast Cancer
Speaker: K. Ribi Brega (Switzerland)

Evidence-Based Management of Symptoms Related to Endocrine Treatment
Speaker: Y. Wengström (Sweden)

Identification and Management of Treatment-Related Symptoms for Breast Cancer Patients Receiving Adjuvant Endocrine Therapy
Speaker: L. Faili (United Kingdom)

Non-Compliance in the Adjuvant Endocrine Treatment of Women With Breast Cancer
Speaker: P. Peyman Hadji (Germany)

Concluding Remarks
Speaker: Y. Wengström (Sweden)

Scientific Symposium: Anti-Angiogenic Strategies for Cancer
16:00 - 18:00
Chair: A.L. Harris (United Kingdom)
Chair: E. Van Cutsem (Belgium)

Introduction
Speaker: A.L. Harris (United Kingdom)

Vasculogenesis or Angiogenesis in Determining Tumour Regrowth After Cancer Therapy
Speaker: P. Carmeliet (Belgium)

Anti-angiogenesis: Local Anti-Tumour Effect but Accelerated Metastases?
Speaker: R.S. Kerbel (Canada)

Biomarkers & Angiogenesis
Speaker: J.V. Heymach (USA)

Concluding Remarks
Speaker: E. Van Cutsem (Belgium)

TUESDAY 27 SEPTEMBER 2011

Scientific Symposium: PARP Inhibiting Strategies: From Molecular Mechanisms to Rational Clinical Application
09:00 - 11:00
Chair: M. Verheij (The Netherlands)
Chair: T. Helleday (United Kingdom)

Scientific Symposium: Tailoring Personalised Medicine for The Future
09:00 - 11:00
Chair: U. Ringborg (Sweden)
Chair: A.H. Ree (Norway)

Introduction
Speaker: U. Ringborg (Sweden)

Biomarkers in Early Phase Therapy Trials
Speaker: A. Adjei (USA)

Personalised Therapy in Breast Cancer
Speaker: S. Linn (The Netherlands)

Personalised Therapy in Lung Cancer
Speaker: R. Rosell (Spain)

Biomarkers: Differences Between Medical Oncology Versus Radiotherapy
Speaker: M. Krause (Germany)

Concluding Remarks
Speaker: A.H. Ree (Norway)

Teaching Lecture: Translational Genomics in Breast Cancer
08:00 - 08:45
Speaker: C. Caldas (United Kingdom)

Special Session: Hitting the Right Pathway: New Drugs for New Targets
13:15 - 14:15
Chair: F. Capuzzo (Italy)

MET Inhibitors
Speaker: P. Jänne (USA)

RAF Inhibitors
Speaker: F. Di Nicolantonio (Italy)

ALK Inhibitors Beyond Lung
Speaker: R. Doebele (USA)

Discussion and Roundup
Introduction
Speaker: M. Verheij (The Netherlands)

Cellular Responses to DNA Damage: Molecular Insights and New Strategies for Cancer Therapy
Speaker: S. Bhide (United Kingdom)

Preclinical Evaluation of PARP Inhibitors in Mouse Models of Human Breast Cancer
Speaker: J. Jonkers (The Netherlands)

Combining PARP Inhibitors With DNA Damaging Agents: Clinical Studies
Speaker: D. Fennell (United Kingdom)

Radiosensitisation By PARP Inhibition
Speaker: A. Chalmers (United Kingdom)

Concluding Remarks
Speaker: T. Helleday (United Kingdom)

YOUNG ONCOLOGISTS

Sunday 25 September 2011

Special Session: Tips and Tricks to Be the Best
■ 13:15 - 14:15
Chair: I.R.H.M. Konings (The Netherlands)
Surgeon
Speaker: A. Maciejewski (Poland)
Clinical Oncologist
Speaker: S. Sleijfer (The Netherlands)
Radiation Oncologist
Speaker: D. Zips (Germany)
Discussion and Roundup

Monday 26 September 2011

Special Session: How to Write and Review a Good Article?
■ 17:00 - 18:00
Chair: M. Hutka (Poland)
The Point of View of the Editor
Speaker: M. Baumann (Germany)
The Point of View of a Statistician
Speaker: L. Collette (Belgium)
How to Get Good Evidence Based Information
Speaker: T. Troiani (Italy)
Discussion and Roundup

Tuesday 27 September 2011

Scientific Symposium:
Managing the Side Effects
■ 09:00 - 11:00
Chair: D. Gabrys (Poland)
Chair: E. Martinelli (Italy)
Introduction
Speaker: D. Gabrys (Poland)

Early and Late Side Effects Related to Surgery
Speaker: C. Verhoef (The Netherlands)

Combination of Radiotherapy and Targeted Agents: What Should We Expect?
Speaker: M. Brada (United Kingdom)

Is It Time to Review the Common Toxicity Criteria in the Era of New Targeted Drugs?
Speaker: J. Jassem (Poland)

How to Follow Up the Acute and the Late Toxicity With New Emerging Therapies?
Speaker: Z. Liao (USA)

Concluding Remarks
Speaker: E. Martinelli (Italy)

Debate: This House Believes That Overall Survival Is the Only Endpoint for Drug Approval
■ 11:30 - 12:30
Moderator: T. Le Chevalier (France)
Overall Survival Is the Only Endpoint for Drug Approval
Speaker in Favour: S. Di Cosimo (Spain)
Overall Survival Is NOT the Only Endpoint for Drug Approval
Speaker Against: M. di Maio (Italy)
Overall Survival Is the Only Endpoint for Drug Approval
Second in Favour: A. Kramar (France)
Overall Survival Is NOT the Only Endpoint for Drug Approval
Second Against: M. Buyse (Belgium)
Questions and Answers Including Audience and Final Vote to See if Audience Have Changed Their Opinion
Leading provider of Oncology content

The European Journal of Cancer (including EJC Supplements), is an international comprehensive Oncology journal that publishes original research, editorial comments, review articles and news on experimental oncology, clinical oncology (medical, paediatric, radiation, surgical), translational oncology, and on cancer epidemiology and prevention.

The European Journal of Cancer (including EJC Supplements) is the official Journal of the European Organisation for Research and Treatment of Cancer (EORTC), the European CanCer Organisation (ECCO), the European Association for Cancer Research (EACR) and the European Society of Breast Cancer Specialists (EUSOMA).

For more information (including online submissions) visit: www.ejcancer.info

OncologySTAT is where Hem/Onc professionals like you go when search engines don’t meet your needs: too many results, most for patients (not professionals like you), and nothing organized or validated. Edited by leaders in Oncology, OncologySTAT has more scientific and practice-changing content than any other oncology website—breaking news, journal scans, abstracts, expert opinion, chemo regimens, drug information, CME and more.

OncologySTAT is also the gateway to tens of thousands of pages of full text, peer-reviewed original research and reviews from over 100 leading cancer journals. Best of all, everything is sorted by cancer type, the way you need it. Come to OncologySTAT for the information and resources that can change how you fight cancer as a practitioner or a researcher. All the answers you need, all in one place.

For more information and to register for FREE visit: www.oncologystat.com

The Lancet Oncology is a lively monthly journal containing original research, reviews, opinion, and news covering international issues relevant to clinical cancer specialists worldwide. The journal has quickly established itself as one of the premier journals worldwide for original research, especially reports from clinical trials. Uniquely, all original research is peer-reviewed via a fast-track service, and successful papers are published within 8 weeks of submission.

For more information visit: www.thelancet.com/oncology

Cancer Cell publishes reports of novel results in any area of cancer research, from molecular and cellular biology to clinical oncology. The work should be not only of exceptional significance within its field but also of interest to researchers outside the immediate area. In addition, Cancer Cell findings in cancer research, diagnosis and treatment. The goal of Cancer Cell is to promote the exchange of ideas and concepts across the entire cancer community, cultivating new areas of basic research and clinical investigation.

Cancer Cell will consider papers for publication in any aspect of cancer biology and clinical research, including (but not limited to): Genetics, epigenetics, genomic instability • Cell signaling and communication • Cell cycle, DNA repair • Diagnostics (molecular profiling, pharmacogenomics) • Telomerase and transformation • Apoptosis • Angiogenesis, metastasis • Animal models • Cancer therapy (rational drug design, small molecule therapeutics) • Epidemiology and prevention.

For more information visit: www.cell.com/cancer-cell
Call for Abstracts

Abstracts can only be submitted online on the ECCO website at: www.ecco-org.eu.

Abstracts submitted by post, fax or E-mail will NOT be accepted.

Abstract submission deadline is 18 April 2011, 09.00 p.m. (21:00 hrs) Central European Time.
The 2011 European Multidisciplinary Cancer Congress abstract submission programme is available on the ECCO website, www.ecco-org.eu.

It is strongly advised that presenting authors should submit their abstract before the day of the deadline, otherwise authors may experience technical delay due to server overload.

The 2011 European Multidisciplinary Cancer Congress Scientific Committee strongly encourages the submission of abstracts on Phase I, Phase II and large Phase III trials coming to an end or having new data available mid 2011. Please refer to “Late-Breaking Abstracts Policy & Regulations” on page 35.

Abstracts on case studies will be rejected.

1. Abstract Policies and Regulations

With the submission of an abstract to 2011 European Multidisciplinary Cancer Congress, the first (presenting) author:

- Warrants that the data and conclusions presented in the abstract have not been presented or published at any meeting of 500 delegates or more prior to the 2011 European Multidisciplinary Cancer Congress
- For important large studies, presented (in part) at previous meetings, authors are encouraged to provide updated data. Violation of this policy may result in a rejection of the submitted abstract.
- Certifies that the information in the abstract is for exclusive presentation in the 2011 European Multidisciplinary Cancer Congress scientific programme and will not be presented as such during the conference at any industry-related satellite symposia.
- States that for all studies involving human or animal subjects, permission has been obtained from the relevant regulatory authority and properly informed consent given where appropriate
- Abstracts that include clinical trial data include the following information in the body of the abstract: Trial abbreviation, Trial Registry Number or ID background, Objective, Design, Population studied (including sample size), Intervention, Outcome measure(s), Analysis, Trial status, Trial sponsor(s)
- Identifies any financial interest in products or processes described in the abstract. The presenting author is requested to tick the “Conflict of interest” box when submitting the abstract and to provide disclosure of interests and relationships through the abstract submission programme. This includes stock ownership, membership on an advisory board or board of directors, corporate-sponsored research, or other substantive relationships.
- Releases the copyright to ECCO and gives permission for the abstract, when selected for presentation, to be published in the 2011 European Multidisciplinary Cancer Congress Abstract book with the European Journal of Cancer Supplement (in printed and electronic format), as well as on the ECCO website.

2. Abstract Preparation and Submission
   a. Abstract Format

- The title of the abstract should be brief, and in Title Case, objectively describing the study. Do not use non-standard abbreviations and commercial names (generic names only).
• **No more than 10 authors** can be listed with institutional affiliations, cities and countries only. Mailing addresses and academic degrees should not be mentioned in the author’s list. For cooperative study groups, you may give the name of the group instead of individual institutional affiliations or include the name of the group in the title of the abstract.

• Abstracts should be structured in such a way as to include the following 4 sections:
  - **Background**: an introductory sentence indicating the purpose of the study
  - **Material and methods**: a brief description of pertinent experimental procedures
  - **Results**: a summary of the results of the research
  - **Conclusions**: a statement of the main conclusions

• The on-line abstract submission procedure will not accept abstracts that exceed **2,500 characters (body of the abstract, including spaces and table)**

• **Only one data table** is permitted in the body of the abstract. Illustration and figures are not allowed and will be deleted if submitted.

• **Abbreviations** may be used if standard or if spelled out and defined at the first use (put in parentheses immediately after the first mention of a term or phrase). Compounds should be mentioned with the generic name, in lower cases. Commercial names are admitted in the text, with an ®, and if in brackets following the generic name, i.e. “generic (Commercial ®)”.

• The abstract must be submitted in **good English**. The Scientific Committee reserve the right to reject those abstracts which are presented in poor English, or may request an immediate revision by the presenter.

**b. Abstract Submission Procedure**

Abstracts must be submitted on-line, through the ECCO website at: [www.ecco-org.eu](http://www.ecco-org.eu).

**Essential information**

• When finished with the online submission, click the **‘FINAL SUBMISSION’ button for the final submission of your abstract**. As a confirmation of your submission, a message will appear on the screen informing you the abstract has been successfully submitted to our database.

• If you need to **edit your abstract** at a later stage please click ‘SAVE AND CLOSE’. This button allows you to update your abstract before final submission. **Please note:** after clicking ‘SAVE AND CLOSE’, your abstract is NOT submitted. You need to return to the abstract submission page, finalise your abstract and click ‘FINAL SUBMISSION’.

• Within 48 hours of submission, the presenting author will receive an e-mail to confirm that ECCO has received the abstract. This confirmation of abstract does not mean your abstract has been selected for presentation.

• In case the confirmation from the 2011 European Multidisciplinary Cancer Congress Secretariat is not received, please contact the secretariat ([pat.vanhove@ecco-org.eu](mailto:pat.vanhove@ecco-org.eu)) within one week after the submission of the abstract.

• Submitting an abstract for presentation in the 2011 European Multidisciplinary Cancer Congress does not constitute registration for the conference. Abstract presenters must register to attend the 2011 European Multidisciplinary Cancer Congress by following the instructions for registration on the website

**Presentation Preference**

Oral, poster or no preference: the final decision on the presentation format will be made by the Scientific Committee.

3. **Topic Categories**

Please select **ONE abstract topic and ONE abstract sub topic which refers to the main subject of the abstract**.

**Keywords**: Authors have to provide **3 keywords** (different from category). The Scientific Committee has the authority to re-categorise and re-key the abstract.

For questions regarding the on-line submission process please email Pat Vanhove at: [pat.vanhove@ecco-org.eu](mailto:pat.vanhove@ecco-org.eu).

For the list of abstract topic categories please see page 37.
4. Abstract Selection Process
Abstracts submitted for presentation in the 2011 European Multidisciplinary Cancer Congress will be reviewed by an international panel of experts in the field of the subject and will be judged solely on the data submitted.

The following presentation formats are applicable at the 2011 European Multidisciplinary Cancer Congress:

**Oral presentation**: the abstract is selected for oral presentation at any of the proffered papers sessions. Abstracts of superior quality can be selected for presentation in a session where discussants will place the research findings into perspective.

**Poster session**: abstracts that have been selected for presentation in poster format will be displayed on poster boards. The posters are grouped by topic and are displayed for four hours. A specific time is devoted to poster viewing.

**Poster discussion session**: experts in the field are chosen to provide a themed overview and discussions of the findings from selected abstracts. First authors of abstracts that have been selected for poster discussion session will be invited to submit the poster electronically prior to the congress (details will follow in due time). Abstracts will be made available two weeks before the Congress. Presenting authors will be contacted to give their consent.

**Withdrawal of abstracts**: Abstracts submitted for the 2011 European Multidisciplinary Cancer Congress can be withdrawn until Wednesday 4 May 2011. After this date, abstracts selected for oral or poster presentation should be presented. If the presenting author of a selected abstract cannot attend, (s)he should assign a replacement and inform ECCO of the replacement as soon as possible.

The presenting author will receive a letter with the result of the review and the Scientific Committee's decision on the abstract by end of June/ beginning of July.

5. ‘Late-Breaking Abstracts’ Policy and Regulations

**Late-Breaking Abstract submission deadline is 10 August 2011, 09.00 p.m. (21:00 hrs) Central European Time.**

**Definition**
• Late-breaking abstracts should highlight novel and practice changing studies. The late-breaking abstract deadline is not intended to be merely an extension of the general submission deadline. It will focus on capturing abstracts with ground-breaking and unique data that would not otherwise have been presented at the Congress.

Examples of suitable late-breaking abstracts might include the results of a practice-changing prospective Phase III clinical trial, a Phase II study showing anti-tumour activity in a novel context, an early clinical trial with novel proof-of-principle data, the demonstration of novel cancer biology with therapeutic implications; in each case the results should not have been fully available by the general abstract submission deadline.

• The data in the abstract must not be published (manuscript or abstract) prior to the Congress.

**Policy**
• Abstracts from translational, Phase I, Phase II or Phase III studies for which preliminary data were not available at the time of the abstract submission deadline of 18 April 2011, will be considered for presentation at the 2011 European Multidisciplinary Cancer Congress.

• Data from the long-term follow-up of previously presented clinical trials may be submitted only if significant new information can be shown. In this case, please ask for special consideration by email.

• Interim analysis of a prospective randomised clinical trial will be considered only if it is performed as planned in the original protocol and is statistically valid. If your abstract involves interim analysis, explain the details of your study in the body of the abstract.
• Late-breaking abstracts will be considered for oral presentation either in proffered papers sessions or in one of the Presidential sessions. If a late-breaking abstract does not meet the criteria for oral presentation in one of these two sessions, the abstract will be rejected.

• Late-breaking abstracts will undergo formal peer-review evaluation by the Scientific Committee.

**Submission**

A call for late-breaking abstracts will be made in June.

**Online submission will be open from 27 July 2011 until 10 August 2011.**

The first (presenting) author must:

• Submit a late breaking abstract by the submission deadline of 10 August 2011.

• Complete the section on the reasons why this abstract should be considered as late-breaking (In order for the abstract to be considered late breaking, this section must be completed).

• Ensure that submission of the abstract follows the general abstract submission guidelines and regulations and the specific guidelines listed above.

• Ensure abstracts that include clinical trial data include the following information in the body of the abstract:
  - Trial abbreviation, Trial Registry Number or ID
  - Background, Objective, Design, Population studied (including sample size), Intervention, Outcome measure(s), analysis, Trial status, Trial sponsor(s)

• Ensure that abstracts contain final results and incorporate statistical analysis. Abstracts submitted stating "results to follow" or similar deferment will not be considered.

**Selection**

• Abstracts will be judged solely on the data submitted. The first (presenting) author will receive confirmation of acceptance or rejection before 27 August 2011.

---

**6. Embargo Policy for Late Breaking, Oral Presentations and Abstracts Selected for Media**

• Abstracts submitted to the 2011 European Multidisciplinary Cancer Congress are considered to be embargoed until the first day of the scientific programme.

• Information contained in the abstract as well as additional data and information to be presented must not be made public before the abstract has been published or presented at the 2011 European Multidisciplinary Cancer Congress.

• The first author and co-authors must not release the research/study to news media.

• If the policy is violated, the abstract will be automatically withdrawn from presentation and from publication online.
### Abstract Topic Categories

<table>
<thead>
<tr>
<th>Topic Sub-Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Basic Science</strong></td>
</tr>
<tr>
<td>Aging and Cancer, Telomerase</td>
</tr>
<tr>
<td>Animal Models of Cancer</td>
</tr>
<tr>
<td>Cancer Cell Metabolism</td>
</tr>
<tr>
<td>Cancer Initiating Cells/Cancer Stem Cells</td>
</tr>
<tr>
<td>Cell Cycle, Cell Death, Senescence, Cell Proliferation</td>
</tr>
<tr>
<td>DNA Damage and Repair</td>
</tr>
<tr>
<td>Epigenetics</td>
</tr>
<tr>
<td>Functional Genomics</td>
</tr>
<tr>
<td>Gene Expression, Transcriptional Regulation</td>
</tr>
<tr>
<td>Genomic Alterations in Cancer</td>
</tr>
<tr>
<td>miRNA Oncogenes</td>
</tr>
<tr>
<td>Receptors and Signal Transduction</td>
</tr>
<tr>
<td>Tumour Suppressor Genes</td>
</tr>
<tr>
<td>Tumour Angiogenesis</td>
</tr>
<tr>
<td>Tumour Microenvironment</td>
</tr>
<tr>
<td>Tumour Progression: Invasion and Metastasis</td>
</tr>
<tr>
<td>Tumour Immunology</td>
</tr>
<tr>
<td>Viral Oncogenesis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Topic Sub-Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Breast Cancer - Advanced Disease</strong></td>
</tr>
<tr>
<td>Basic Science</td>
</tr>
<tr>
<td>Multi-Modality</td>
</tr>
<tr>
<td>Radiotherapy</td>
</tr>
<tr>
<td>Surgery</td>
</tr>
<tr>
<td>Systemic Therapy</td>
</tr>
<tr>
<td>Translational Research</td>
</tr>
<tr>
<td>Other</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Topic Sub-Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Breast Cancer – Early Disease</strong></td>
</tr>
<tr>
<td>Basic Science</td>
</tr>
<tr>
<td>Multi-Modality</td>
</tr>
<tr>
<td>Radiotherapy</td>
</tr>
<tr>
<td>Surgery</td>
</tr>
<tr>
<td>Systemic Therapy</td>
</tr>
<tr>
<td>Translational Research</td>
</tr>
<tr>
<td>Other</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Topic Sub-Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cancer in the Older Patient</strong></td>
</tr>
<tr>
<td>Epidemiology</td>
</tr>
<tr>
<td>Multi-Modality</td>
</tr>
<tr>
<td>Radiotherapy</td>
</tr>
<tr>
<td>Surgery</td>
</tr>
<tr>
<td>Systemic Therapy</td>
</tr>
<tr>
<td>Translational Research</td>
</tr>
<tr>
<td>Other</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Topic Sub-Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Central Nervous System</strong></td>
</tr>
<tr>
<td>Basic Science</td>
</tr>
<tr>
<td>Multi-Modality</td>
</tr>
<tr>
<td>Radiotherapy</td>
</tr>
<tr>
<td>Surgery</td>
</tr>
<tr>
<td>Systemic Therapy</td>
</tr>
<tr>
<td>Translational Research</td>
</tr>
<tr>
<td>Other</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Topic Sub-Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Diagnostic/Biomarkers</strong></td>
</tr>
<tr>
<td>Expression Profiling</td>
</tr>
<tr>
<td>Predictive Biomarkers</td>
</tr>
<tr>
<td>Prognostic Biomarkers</td>
</tr>
<tr>
<td>Other</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Topic Sub-Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Drug Development</strong></td>
</tr>
<tr>
<td>Angiogenic Inhibitors</td>
</tr>
<tr>
<td>Apoptosis Inducers</td>
</tr>
<tr>
<td>Cyclins and CDKs</td>
</tr>
<tr>
<td>DNA Repair Mechanisms</td>
</tr>
<tr>
<td>Drug Design</td>
</tr>
<tr>
<td>Drug Resistance and Modifiers</td>
</tr>
<tr>
<td>Drug Screening</td>
</tr>
<tr>
<td>Drug Synthesis</td>
</tr>
<tr>
<td>Formulation Research</td>
</tr>
<tr>
<td>Immunological Targets</td>
</tr>
<tr>
<td>Monoclonal Antibodies and Targeted Toxins/Nuclides</td>
</tr>
<tr>
<td>Natural Products and Marine Compounds</td>
</tr>
<tr>
<td>New Molecular Targets</td>
</tr>
<tr>
<td>Radiation Interactive Agents</td>
</tr>
<tr>
<td>Signal Transduction Modulators</td>
</tr>
<tr>
<td>Telomerase-Targeting Agents</td>
</tr>
<tr>
<td>Topoisomerase Inhibitors</td>
</tr>
<tr>
<td>Toxicology</td>
</tr>
<tr>
<td>Tubulin-Interacting Agents</td>
</tr>
<tr>
<td>Tumour Stem Cells</td>
</tr>
<tr>
<td>Tyrosine Kinase Inhibitors</td>
</tr>
<tr>
<td>Vaccines</td>
</tr>
<tr>
<td>Other</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Topic Sub-Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Epidemiology and Prevention</strong></td>
</tr>
<tr>
<td>General Epidemiology</td>
</tr>
<tr>
<td>Molecular Epidemiology</td>
</tr>
<tr>
<td>Primary Prevention</td>
</tr>
<tr>
<td>Secondary Prevention</td>
</tr>
<tr>
<td>Other</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Topic Sub-Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gastrointestinal Malignancies - Colorectal Cancer</strong></td>
</tr>
<tr>
<td>Basic Science</td>
</tr>
<tr>
<td>Multi-Modality</td>
</tr>
<tr>
<td>Radiotherapy</td>
</tr>
<tr>
<td>Surgery</td>
</tr>
<tr>
<td>Systemic Therapy</td>
</tr>
<tr>
<td>Translational Research</td>
</tr>
<tr>
<td>Other</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Topic Sub-Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Gastrointestinal Malignancies - Noncolorectal Cancer</strong></td>
</tr>
<tr>
<td>Basic Science</td>
</tr>
<tr>
<td>Multi-Modality</td>
</tr>
<tr>
<td>Radiotherapy</td>
</tr>
<tr>
<td>Surgery</td>
</tr>
<tr>
<td>Systemic Therapy</td>
</tr>
<tr>
<td>Translational Research</td>
</tr>
<tr>
<td>Other</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Topic Sub-Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Genitourinary Malignancies - Other</strong></td>
</tr>
<tr>
<td>Basic Science</td>
</tr>
<tr>
<td>Multi-Modality</td>
</tr>
<tr>
<td>Radiotherapy</td>
</tr>
<tr>
<td>Surgery</td>
</tr>
<tr>
<td>Systemic Therapy</td>
</tr>
<tr>
<td>Translational Research</td>
</tr>
<tr>
<td>Other</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Topic Sub-Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Genitourinary Malignancies - Prostate Cancer</strong></td>
</tr>
<tr>
<td>Basic Science</td>
</tr>
<tr>
<td>Multi-Modality</td>
</tr>
<tr>
<td>Radiotherapy</td>
</tr>
<tr>
<td>Surgery</td>
</tr>
<tr>
<td>Systemic Therapy</td>
</tr>
<tr>
<td>Translational Research</td>
</tr>
<tr>
<td>Other</td>
</tr>
<tr>
<td>Topic Sub-Topic</td>
</tr>
<tr>
<td>----------------</td>
</tr>
<tr>
<td><strong>Gynaecological Cancer</strong></td>
</tr>
<tr>
<td>Basic Science</td>
</tr>
<tr>
<td>Multi-Modality</td>
</tr>
<tr>
<td>Radiotherapy</td>
</tr>
<tr>
<td>Surgery</td>
</tr>
<tr>
<td>Systemic Therapy</td>
</tr>
<tr>
<td>Translational Research</td>
</tr>
<tr>
<td>Other</td>
</tr>
<tr>
<td><strong>Haematological Malignancies and Myeloma</strong></td>
</tr>
<tr>
<td>Basic Science</td>
</tr>
<tr>
<td>Radiotherapy</td>
</tr>
<tr>
<td>Systemic Therapy</td>
</tr>
<tr>
<td>Translational Research</td>
</tr>
<tr>
<td>Other</td>
</tr>
<tr>
<td><strong>Head and Neck Cancer</strong></td>
</tr>
<tr>
<td>Basic Science</td>
</tr>
<tr>
<td>Multi-Modality</td>
</tr>
<tr>
<td>Radiotherapy</td>
</tr>
<tr>
<td>Surgery</td>
</tr>
<tr>
<td>Systemic Therapy</td>
</tr>
<tr>
<td>Translational Research</td>
</tr>
<tr>
<td>Other</td>
</tr>
<tr>
<td><strong>Imaging</strong></td>
</tr>
<tr>
<td>CT-Scan</td>
</tr>
<tr>
<td>Molecular Imaging</td>
</tr>
<tr>
<td>MRI</td>
</tr>
<tr>
<td>New Methodologies</td>
</tr>
<tr>
<td>Nuclear Medicine</td>
</tr>
<tr>
<td>US</td>
</tr>
<tr>
<td>Other</td>
</tr>
<tr>
<td><strong>Lung cancer - Localised / Local Regional</strong></td>
</tr>
<tr>
<td>Basic Science</td>
</tr>
<tr>
<td>Multi-Modality</td>
</tr>
<tr>
<td>Radiotherapy</td>
</tr>
<tr>
<td>Surgery</td>
</tr>
<tr>
<td>Systemic Therapy</td>
</tr>
<tr>
<td>Translational Research</td>
</tr>
<tr>
<td>Other</td>
</tr>
<tr>
<td><strong>Lung Cancer - Metastatic</strong></td>
</tr>
<tr>
<td>Basic Science</td>
</tr>
<tr>
<td>Multi-Modality</td>
</tr>
<tr>
<td>Radiotherapy</td>
</tr>
<tr>
<td>Surgery</td>
</tr>
<tr>
<td>Systemic Therapy</td>
</tr>
<tr>
<td>Translational Research</td>
</tr>
<tr>
<td>Other</td>
</tr>
<tr>
<td><strong>Melanoma and Skin Cancer</strong></td>
</tr>
<tr>
<td>Basic Science</td>
</tr>
<tr>
<td>Multi-Modality</td>
</tr>
<tr>
<td>Radiotherapy</td>
</tr>
<tr>
<td>Surgery</td>
</tr>
<tr>
<td>Systemic Therapy</td>
</tr>
<tr>
<td>Translational Research</td>
</tr>
<tr>
<td>Other</td>
</tr>
<tr>
<td><strong>Radiobiology/Radiation Physics/ Radiotherapy Techniques</strong></td>
</tr>
<tr>
<td>Advanced Technologies</td>
</tr>
<tr>
<td>Biomarkers for Radiation Oncology</td>
</tr>
<tr>
<td>Clinical radiation Physics</td>
</tr>
<tr>
<td>Clinical Radiobiology</td>
</tr>
<tr>
<td>Combined Treatments</td>
</tr>
<tr>
<td>Frontiers in Radiation Oncology</td>
</tr>
<tr>
<td>Health Economics in Radiation Oncology</td>
</tr>
<tr>
<td>Imaging for Radiotherapy</td>
</tr>
<tr>
<td>Mathematics and IT for Radiation Oncology</td>
</tr>
<tr>
<td>Modification of radiation response</td>
</tr>
<tr>
<td>Monitoring in Radiotherapy</td>
</tr>
<tr>
<td>Multidisciplinary Team Development</td>
</tr>
<tr>
<td>Prediction and Stratification in Radiation Oncology</td>
</tr>
<tr>
<td>Professional Development</td>
</tr>
<tr>
<td>Quality Assurance</td>
</tr>
<tr>
<td>Radiation Physics</td>
</tr>
<tr>
<td>Radiation Physics</td>
</tr>
<tr>
<td>Radiation Physics In Radiation Oncology</td>
</tr>
<tr>
<td>Technology Assessment in Radiation Oncology</td>
</tr>
<tr>
<td>Treatment Planning</td>
</tr>
<tr>
<td>Other</td>
</tr>
<tr>
<td><strong>Sarcoma: Soft Tissue and Bone</strong></td>
</tr>
<tr>
<td>Basic Science</td>
</tr>
<tr>
<td>Multi-Modality</td>
</tr>
<tr>
<td>Radiotherapy</td>
</tr>
<tr>
<td>Surgery</td>
</tr>
<tr>
<td>Systemic Therapy</td>
</tr>
<tr>
<td>Translational Research</td>
</tr>
<tr>
<td>Other</td>
</tr>
<tr>
<td><strong>Surgical Techniques</strong></td>
</tr>
<tr>
<td>Image-Guided Surgery</td>
</tr>
<tr>
<td>Local Ablative Treatment</td>
</tr>
<tr>
<td>Oncoplastic Surgery</td>
</tr>
<tr>
<td>Regional Treatment</td>
</tr>
<tr>
<td>Robotic-Assisted Surgery</td>
</tr>
<tr>
<td>Other</td>
</tr>
<tr>
<td><strong>Regulatory/Trial Methodology/Pharmacy</strong></td>
</tr>
<tr>
<td><strong>Surgical Techniques</strong></td>
</tr>
<tr>
<td>Image-Guided Surgery</td>
</tr>
<tr>
<td>Local Ablative Treatment</td>
</tr>
<tr>
<td>Oncoplastic Surgery</td>
</tr>
<tr>
<td>Regional Treatment</td>
</tr>
<tr>
<td>Robotic-Assisted Surgery</td>
</tr>
<tr>
<td>Other</td>
</tr>
<tr>
<td><strong>Sarcoma: Soft Tissue and Bone</strong></td>
</tr>
<tr>
<td>Topic</td>
</tr>
<tr>
<td>------------------------</td>
</tr>
<tr>
<td><strong>Symptom Science</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Translational Research</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Onco-Technology</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>Other</strong></td>
</tr>
</tbody>
</table>

**ecancer**

Leading cancer communication in Europe

- **ecancerjournal**
  - Open access journal from the European Institute of Oncology
  - No subscription charges
  - Independent, not for profit
  - Fast turnaround of articles

- **ecancer.tv**
  - Over 700 interviews with leading experts
  - Watch, comment and share

Over 10,000 users from 114 countries
Over 100 articles and more than 700 videos

BE PART OF THE COMMUNITY AT www.ecancer.eu

Essential information. Trusted Source. On-demand
Fellowship Grants & Educational Awards

1. The 2011 European Multidisciplinary Cancer Congress Fellowship Grants

Through the generosity of the 2011 European Multidisciplinary Cancer Congress Sponsors, a number of Fellowship Grants are offered to young researchers (doctors, basic scientists and nurses) from countries with limited resources to attend the Congress.

To meet the requirements to be considered for a fellowship grant the applicant should:

- Submit an abstract for the 2011 European Multidisciplinary Cancer Congress. Applicants whose abstracts have been accepted for an oral or poster presentation at the 2011 European Multidisciplinary Cancer Congress will be considered first.
- Be under the age of 40 and have a primary focus in clinical or experimental oncology or cancer nursing.
- Provide a letter of support from the Head of the Department/Organisation stating that the applicant is not the recipient of any other financial support, including a copy of the submitted abstract.
- Provide a two page CV (including date of birth).

The deadline for receipt of applications is 18 April 2011 (abstract submission deadline). Incomplete applications will not be considered.

Each Fellowship Grant shall be worth a free registration, free accommodation for a maximum of 4 nights and reimbursement of travel costs up to a maximum of 500 EUR (reimbursement after the Congress).

Please complete the online application form on the ECCO website at: www.ecco-org.eu.

2. ECCO/EJC Young Investigator’s Award

ECCO – the European CanCer Organisation and EJC - European Journal of Cancer are pleased to announce the ECCO/EJC Young Investigator’s Award, to be presented at 2011 European Multidisciplinary Cancer Congress.

The ECCO/EJC Young Investigator’s Award is open to young basic scientists and clinical oncologists of all disciplines relevant to cancer research. The Award will be given to a young scientist or doctor in the field of basic, translational or clinical oncology research for recent original work in cancer research, treatment or care.

The following application criteria will apply:

- Candidates should be junior (within 5 years of completion of PhD or specialist training).
- Candidates should have completed the submitted work in the period between April 2009 and April 2011.
- Submissions should be sent in by the candidate together with a reference letter from their Head of Department.
- The work may be the result of individual research or the result of a thesis completed in the field of basic, translational or clinical research.
- Candidates should commit themselves to write an original paper in English on the scientific work carried out (for publication in EJC).

The application should include the following documents:

- A summary of the research work (maximum 2 pages) and copies of recently published or submitted manuscripts of the applicants work, to be submitted in English.
- A curriculum vitae and a list of publications.
- A supporting letter from the Head of Department.
Applications will be reviewed by the 2011 European Multidisciplinary Cancer Congress Committee Chairs and the Editor-in-Chief of EJC.

The winner of the ECCO/EJC Young Investigator’s Award will receive a prize of 4000 EUR, free registration for the 2011 European Multidisciplinary Cancer Congress, free accommodation in Stockholm for the period of the Congress and reimbursement of travel expenses and the opportunity to give an oral presentation of the work at 2011 European Multidisciplinary Cancer Congress.

**Deadline for applications: May 15, 2011.**

Applications should be sent to Simona Androni, Scientific Programme Co-ordinator via Email: simona.androni@ecco-org.eu. Successful applicants will be notified in the course of July 2011.

### 3. ECCO – the European CanCer Organisation/EJC Young Investigator’s Poster Awards

We are also pleased to announce the ECCO/EJC Young Investigator’s Poster Awards, which will be selected and presented during the 2011 European Multidisciplinary Cancer Congress.

This Award is open to young basic scientists and clinical oncologists of all disciplines relevant to cancer research.

The Award will be given to a young scientist or doctor in the field of basic, translational or clinical oncology research for original work in cancer research, treatment or care.

**The following further application criteria will apply:**

- Candidates should be junior (within 5 years of completion of PhD or specialist training).
- Candidates should have submitted an abstract to the congress.
- Candidates must indicate that they are young investigators when submitting their abstract.

Selection of the award winners will be made by the Scientific Chairs during the Congress and there will be three awards which will be presented throughout the meeting.
Registration

Registration is now open online - please visit: www.ecco-org.eu.

(select 'Congresses and conferences').

Participants are encouraged to register early in order to benefit from significant savings on fees:

<table>
<thead>
<tr>
<th>'Deadline' Applies to Both Receipt of Registration and Payment</th>
<th>Early Rate Deadline: 04 April 2011</th>
<th>Regular Rate Deadline: 08 August 2011</th>
<th>Late Rate As of 09 August 2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Members *</td>
<td>475 EUR</td>
<td>695 EUR</td>
<td>1,095 EUR</td>
</tr>
<tr>
<td>Non-Members</td>
<td>695 EUR</td>
<td>995 EUR</td>
<td>1,095 EUR</td>
</tr>
<tr>
<td>Emerging Economy Rate **</td>
<td>125 EUR</td>
<td>Not available</td>
<td>Not available</td>
</tr>
<tr>
<td>Nursing Rate ***</td>
<td>375 EUR</td>
<td>475 EUR</td>
<td>575 EUR</td>
</tr>
<tr>
<td>Students/Junior Participant 'in training' ****</td>
<td>170 EUR</td>
<td>170 EUR</td>
<td>170 EUR</td>
</tr>
<tr>
<td>Patient Advocate******</td>
<td>225 EUR</td>
<td>225 EUR</td>
<td>225 EUR</td>
</tr>
<tr>
<td>Spouse Ticket ******</td>
<td></td>
<td>95 EUR</td>
<td></td>
</tr>
</tbody>
</table>

All registration fees include local VAT (25%).

* Discounted membership rates apply for individuals who are member of one of the following professional associations: EACR, ESMO, ESSO, ESTRO, SIOPE, EANO, EAU, EORTC, ESGO, ESO, ESOP, EUSOMA, BIG, EANM, EBMT, ECL, FAC, OECI, UICC.

** Emerging Economy Rate is applied to individuals from low-income and lower-middle-income economies according to the World Bank listing available at: http://data.worldbank.org/about/country-classifications/country-and-lending-groups

*** Including EONS Members

**** Confirmation of 'in training' status and a letter from the Head of Department is required. These documents have to be sent to the 2011 Stockholm Congress Secretariat by Fax: +32 2 775 02 00.

****** Including members of EUROPA DONNA, EUROPA UOMO, Euroskin, Myeloma Euronet.

******* This ticket includes access to the Welcome Reception on Friday, 23 September 2011 as well as a Sightseeing Tour of Stockholm on Saturday, 24 September 2011.

Please note: access to Scientific Sessions or the Exhibition is NOT permitted.

For information regarding group registration, accommodation and travel through the 2011 Stockholm Congress officially appointed local housing agent and airline network please visit: www.ecco-org.eu (select 'Congresses and conferences').
Registration Form

TITLE & CONTACT DETAILS

☐ Prof.  ☐ Dr.  ☐ Mr.  ☐ Mrs.  ☐ Ms.

Last Name: .......................................................... First Name: ..........................................................

Institute/Company: .......................................................... Department: ..........................................................

Address: ..........................................................................................................................................

City: .......................................................... Postcode: .......................................................... Country: ..........................................................

International Tel. Number: .......................................................... International Fax Number: ..........................................................

Email: ..........................................................................................................................................

BILLING ADDRESS

Institute/Company: ..........................................................

Address: ..........................................................................................................................................

City: .......................................................... Postcode: ..........................................................

Country: ..........................................................

International Tel. Number: .......................................................... International Fax Number: ..........................................................

Email: ..........................................................................................................................................

SPECIALISATION IN MAIN TUMOUR TYPES (PLEASE SELECT ALL THAT APPLY)

☐ Breast  ☐ Bladder  ☐ Blood  ☐ Bone  ☐ Brain  ☐ Colorectal  ☐ Cervix  ☐ Head and Neck
☐ Kidney  ☐ Liver  ☐ Lung  ☐ Melanoma and Skin  ☐ Neuroendocrine  ☐ Ocular  ☐ Ovarian  ☐ Pancreatic
☐ Prostate  ☐ Soft Tissue Sarcoma  ☐ Stomach  ☐ Thyroid  ☐ Other  ☐ All

AREA OF MAIN INTEREST (PLEASE SELECT ALL THAT APPLY)

☐ Advocacy  ☐ Basic Science  ☐ Clinical Research  ☐ Drug Development  ☐ Early Drug Development  ☐ Geriatric Oncology
☐ Nursing  ☐ Paediatrics  ☐ Palliative Care  ☐ Pathology  ☐ Pharmacy  ☐ Psychosocial Oncology
☐ Policy  ☐ Radiotherapy  ☐ Systemic Therapy  ☐ Surgery  ☐ Translational Research  ☐ Other

PROFESSION

☐ Basic scientist  ☐ Clinical trial coordinator  ☐ General physician  ☐ General surgeon  ☐ Gynaecologist  ☐ Haematologist  ☐ Medical affairs  ☐ Medical oncologist
☐ Neurologist  ☐ Neuro-oncologist  ☐ Neuro-surgeon  ☐ Nurse  ☐ Oncology pharmacist  ☐ Paediatric oncologist  ☐ Patient advocate  ☐ Pathologist
☐ Radiologist  ☐ Radiotherapist  ☐ Statistician  ☐ Student  ☐ Surgical oncologist  ☐ Translational scientist  ☐ Urologist  ☐ Other

PROFESSIONAL MEMBERSHIP

☐ BIG  ☐ EACR  ☐ EANM  ☐ EANO  ☐ EAU  ☐ EBMT  ☐ ECL  ☐ EONS
☐ EORTC  ☐ ESGO  ☐ ESMO  ☐ ESO  ☐ ESOP  ☐ ESSO  ☐ ESTRO  ☐ Europa Donna
☐ Europa Uomo  ☐ EURSKIN  ☐ EUROMEDICAL  ☐ Flims Alumni Club  ☐ Myeloma EuropeNet  ☐ OECD  ☐ SIOP (Europe)  ☐ UICC
REGISTRATION FEES
(please tick as appropriate)

<table>
<thead>
<tr>
<th>Method of Payment / Credit Card Type</th>
<th>Early Rate Deadline: 04 April 2011</th>
<th>Regular Rate Deadline: 08 August 2011</th>
<th>Late Rate As of 09 August 2011</th>
</tr>
</thead>
<tbody>
<tr>
<td>Members *</td>
<td>□ 475 EUR</td>
<td>□ 695 EUR</td>
<td>□ 1095 EUR</td>
</tr>
<tr>
<td>Non-Members</td>
<td>□ 695 EUR</td>
<td>□ 995 EUR</td>
<td>□ 1095 EUR</td>
</tr>
<tr>
<td>Emerging Economy Rate **</td>
<td>□ 125 EUR</td>
<td>Not available</td>
<td>Not available</td>
</tr>
<tr>
<td>Nursing Rate ***</td>
<td>□ 375 EUR</td>
<td>□ 475 EUR</td>
<td>□ 575 EUR</td>
</tr>
<tr>
<td>Students/Junior Participant 'in training' ****</td>
<td>□ 170 EUR</td>
<td>□ 170 EUR</td>
<td>□ 170 EUR</td>
</tr>
<tr>
<td>Patient Advocate *****</td>
<td>□ 225 EUR</td>
<td>□ 225 EUR</td>
<td>□ 225 EUR</td>
</tr>
<tr>
<td>Spouse Ticket *****</td>
<td></td>
<td></td>
<td>□ 95 EUR</td>
</tr>
</tbody>
</table>

All registration fees include local VAT (25%).

* Discounted membership rates apply for individuals who are member of one of the following professional associations: EACR, ESMO, ESTRO, SIDPE, SANIO, EAU, EORTC, ESGO, ESO, ESDP, EUSOMA, BIC, EANM, EBMRT, ECI, FAC, OECI, UIIC.

Stating the membership number is obligatory: .............................................................

** Emerging Economy Rate is applied to individuals from low-income and lower-middle-income economies according to the World Bank listing available at: http://data.worldbank.org/about/country-classifications/country-and-lending-groups

*** Including EONS Members

**** Confirmation of ‘in training’ status and a letter from the Head of Department is required. These documents have to be sent to the 2011 Stockholm Congress Secretariat by Fax: +32 2 775 02 00.

***** Including members of Europa Donna, Europa Uomo, Euroskin, Myeloma Euronet.

****** This ticket includes access to the Welcome Reception on Friday, 23 September 2011 as well as a Sightseeing Tour of Stockholm on Saturday, 24 September 2011. Please note: access to Scientific Sessions or the Exhibition is NOT permitted.

METHOD OF PAYMENT / CREDIT CARD TYPE

Paid by credit card (preferred)

□ Eurocard/Mastercard  □ Visa  □ American Express

Card Number: ........................................................................................................ Expiry Date: ........................................................................................................ Control/CVC-Code: ........................................................................................................

Owner’s name as shown on the card: ........................................................................... Owner’s signature: .................................................................................................

Date: ........................................................................................................ Owner’s signature: .................................................................................................

Remitted by bank transfer (accepted until 29 August 2011 in EUR)

To the 2011 Stockholm Congress Registration Account

Account number: 733-034 89 79-03 // IBAN BE21 7330 3489 7903

BIC/SWIFT Code: KREDBEBB // KBC Bank, Chaussée de Wavre 1662, B-1160 Brussels, Belgium

Please clearly indicate the name of the participant and 2011 Stockholm Congress in all your remittances.

REPLACEMENTS AND CANCELLATIONS

Replacements (= delegate name change) of confirmed registrations are subject to a charge of 95 EUR per participant. Cancellations of confirmed registrations are subject to a charge of 125 EUR per participant provided the cancellation is received by 08 August 2011. For cancellations received after this date no refunds will be made.

By completing this form I accept the terms and conditions of registration mentioned above. If posting or faxing please sign and date below.

Date: ........................................................................................................ Signature: .................................................................................................

The 2011 European Multidisciplinary Cancer Congress Secretariat can be reached at:

ECCO – the European CanCer Organisation

Avenue E. Mounier 83 - B 1200 Brussels - Belgium

Telephone: +32 2 775 02 00 - Fax: +32 2 775 02 01 - Email: registration@ecco-org.eu
### Scientific Programme Tracks: Chairs & Experts

#### Basic Science
- **Track Chair** C. Dive, UK
- **Track Chair** R. J. White, UK
  - J. Celis, DK
  - N. Cordes, DE
  - G. Giaccone, USA
  - J. Seoane, ES
  - K. Wiman, SE
  - B. Wouters, CA

#### Breast Cancer - Advanced Disease
- **Track Chair** J. Bergh, SE
  - F. Andre, FR
  - A. Di Leo, IT
  - T. Helleday, UK
  - T. Kühn, DE
  - R. Orrechia, IT
  - C. Swanton, UK
  - C.J.H. van de Velde, NL

#### Breast Cancer - Early Disease
- **Track Chair** C. Sotiriou, BE
  - J. r. Yarnold, UK
  - S. Delaloge, FR
  - C. Isacke, UK
  - M. Leidenius, FI
  - P. Poortmans, NL
  - r. Sainsbury, UK
  - F. Sardanelli, IT
  - S. Strömblad, SE
  - G. Vlastos, CH

#### Cancer in the Older Patient
- **Track Chair** J. P. Droz, FR
  - J. Kuzmerska, PL
  - R.A. Audisio, UK
  - C. Bokemeyer, DE
  - G.-J. Liefers, NL
  - H. Langendijk, NL
  - S. Monfardini, IT
  - P. Scalieti, BE

#### Central Nervous System
- **Track Chair** M. Hegi, CH
- **Track Chair** R. Grant, UK
  - O. Chiot, FR
  - P. Lichter, DE
  - C. Blam, AT
  - S. Short, UK
  - W. Wick, DE

#### Diagnostic/Biomarkers
- **Track Chair** F. Blackhall, UK
- **Track Chair** M. van de Vijver, NL
  - P. Hainaut, FR
  - V. Lazar, FR
  - B. Naume, NO
  - F. Penault-Llorca, FR
  - R.A.E. M. Tonnellaar, NL

#### Drug Development
- **Track Chair** J. Baselga, ES
- **Track Chair** S. Steijfer, NL
  - E. Calvo, ES
  - F. Cardoso, BE
  - E. Cohen-Jonathan-Moyal, FR
  - S. Marsmani, IT
  - H. Newell, UK
  - P. Workman, UK

#### Education Track
- **Track Chair** D. Schrijvers, BE
  - R. Stael, CH
  - R.A. Audisio, UK
  - A. Barret, UK
  - A. Cervantes, ES
  - F. Ciardello, IT
  - M. Dicato, LU
  - V. Jendrossek, UK
  - S. J. O'Connor, NL
  - N. Pavlidis, CR
  - R. Riccardi, IT
  - R. Soffetti, IT

#### Epidemiology, Primary and Secondary Prevention
- **Track Chair** C. P. Wild, FR
  - P. Hall, SE
  - A. Gescher, UK
  - B. Kocic, SR
  - N. Malats, ES
  - H. Storm, DK
  - A.M. Thulstrup, DK

#### Gastrointestinal Malignancies - Colorectal Cancer
- **Track Chair** E. Van Cutsem, BE
  - V. Valentini, IT
  - B.M. Ghadimi, DE
  - B. Glimelius, SE
  - K. Haustermans, BE
  - L. Pahlman, SE
  - J. Tabernero, ES
  - I. Tomlinson, UK

#### Gastrointestinal Malignancies - Noncolorectal Cancer
- **Track Chair** R. Adam, FR
  - J. Llovet, ES
  - B. Bonsing, NL
  - T. Brunner, UK
  - D. Cunningham, UK
  - M.A. Gambacorta, IT
  - T. Lehnert, DE
  - F. Lordick, DE

#### Genitourinary Malignancies - Other
- **Track Chair** J. Bellmunt, ES
- **Track Chair** P. Hoskin, UK
  - M. De Santis, AT
  - A. Kilte, UK
  - Z. Krikali, TR
  - S. Oudard, FR

#### Genitourinary Malignancies - Prostate Cancer
- **Track Chair** K. Fizazi, FR
  - M.-O. Grimm, DE
  - C. Belka, DE
  - A. Bossi, FR
  - J. De Bono, UK
  - T. De Reijke, NL
  - F. Guedea, ES
  - M.P. Mattkainen, FI

#### Gynaecological Cancer
- **Track Chair** S. Kaye, UK
- **Track Chair** P. Morice, FR
  - R. Brown, UK
  - N. Colombo, IT
  - M. D'Incalci, IT
  - C. Haie-Meder, FR
  - R. Potter, AT
  - C.G. Trap, NO
  - A.T. Vlastos, CH

#### Haematological Malignancies and Myeloma
- **Track Chair** V. Ribrag, FR
- **Track Chair** L. Bullinger, DE
  - J. Delaube, NO
  - M.H. Dreyling, DE
  - H.T. Eich, DE
  - T. Grimsky, FR
  - R. Kuppers, DE

#### Head and Neck Cancer
- **Track Chair** S. Subramanian, RU
- **Track Chair** K. Harrington, UK
  - A. Dietz, DE
  - S. Faivre, FR
  - J. Giral, ES
  - V. Gregoire, BE
  - R. Knecht, DE
  - M. Mefano, IT

#### Imaging
- **Track Chair** N. Lassau, FR
- **Track Chair** W. Weber, DE
  - S. Del Vecchio, IT
  - E. Even-Sapir, IL
  - P. Friedl, NL
  - H.-U. Kauczor, DE
  - V. Khoo, UK
  - U. Nestle, DE
### Industry

<table>
<thead>
<tr>
<th>Track Chair</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>D.R. Parkinson</td>
<td>USA</td>
</tr>
<tr>
<td>M.L. Rothenberg</td>
<td>USA</td>
</tr>
<tr>
<td>D. Chang</td>
<td>USA</td>
</tr>
<tr>
<td>S. Frings</td>
<td>SE</td>
</tr>
<tr>
<td>S. Johansson</td>
<td>USA</td>
</tr>
<tr>
<td>A. Riva</td>
<td>USA</td>
</tr>
<tr>
<td>G. Saeter</td>
<td>USA</td>
</tr>
<tr>
<td>T. Suto</td>
<td>USA</td>
</tr>
<tr>
<td>M. Victor</td>
<td>FR</td>
</tr>
</tbody>
</table>

### Lung Cancer – Localised/Local Regional

<table>
<thead>
<tr>
<th>Track Chair</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>T. Le Chevalier</td>
<td>FR</td>
</tr>
<tr>
<td>D. de Ruyscher</td>
<td>NL</td>
</tr>
<tr>
<td>M. Brada</td>
<td>UK</td>
</tr>
<tr>
<td>K.O. Byrne</td>
<td>IE</td>
</tr>
<tr>
<td>P. Darteville</td>
<td>FR</td>
</tr>
<tr>
<td>S. Senan</td>
<td>NL</td>
</tr>
<tr>
<td>R. Stahel</td>
<td>CH</td>
</tr>
<tr>
<td>P. Van Schil</td>
<td>BE</td>
</tr>
</tbody>
</table>

### Lung Cancer – Metastatic

<table>
<thead>
<tr>
<th>Track Chair</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>R. Dziadziuszko</td>
<td>PL</td>
</tr>
<tr>
<td>L. Paz-Ares</td>
<td>ES</td>
</tr>
<tr>
<td>G.T. Brustugun</td>
<td>NO</td>
</tr>
<tr>
<td>C. Le Pechoux</td>
<td>FR</td>
</tr>
<tr>
<td>R. Perona</td>
<td>ES</td>
</tr>
<tr>
<td>J. Schirren</td>
<td>DE</td>
</tr>
<tr>
<td>M. Thomas</td>
<td>DE</td>
</tr>
</tbody>
</table>

### Melanoma and Skin Cancer

<table>
<thead>
<tr>
<th>Track Chair</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>A.M.M. Eggermont</td>
<td>NL</td>
</tr>
<tr>
<td>R. Marais</td>
<td>UK</td>
</tr>
<tr>
<td>S. Aamdal</td>
<td>NO</td>
</tr>
<tr>
<td>M. Hocesvari</td>
<td>SI</td>
</tr>
<tr>
<td>C. Robert</td>
<td>FR</td>
</tr>
<tr>
<td>S. Schneebaum</td>
<td>IL</td>
</tr>
<tr>
<td>M.S. Soengas</td>
<td>ES</td>
</tr>
</tbody>
</table>

### Oncology Nursing

<table>
<thead>
<tr>
<th>Track Chair</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>S. Kav</td>
<td>TR</td>
</tr>
<tr>
<td>L. Sharp</td>
<td>SE</td>
</tr>
<tr>
<td>S. Faithfull</td>
<td>UK</td>
</tr>
<tr>
<td>D. Kelly</td>
<td>UK</td>
</tr>
<tr>
<td>A. Molassioti</td>
<td>UK</td>
</tr>
<tr>
<td>Y. Wengström</td>
<td>SE</td>
</tr>
</tbody>
</table>

### Oncopoly

<table>
<thead>
<tr>
<th>Track Chair</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>D. Kerr</td>
<td>UK</td>
</tr>
<tr>
<td>M. Baumann</td>
<td>DE</td>
</tr>
<tr>
<td>P.G. Casali</td>
<td>IT</td>
</tr>
<tr>
<td>J. Celis</td>
<td>DK</td>
</tr>
<tr>
<td>A.M.M. Eggermont</td>
<td>NL</td>
</tr>
<tr>
<td>D. Khayat</td>
<td>FR</td>
</tr>
<tr>
<td>M. Piccart</td>
<td>BE</td>
</tr>
<tr>
<td>M. Pierotti</td>
<td>IT</td>
</tr>
<tr>
<td>K. Redmond</td>
<td>IT</td>
</tr>
<tr>
<td>U. Ringborg</td>
<td>SE</td>
</tr>
<tr>
<td>G. Wiesler</td>
<td>DE</td>
</tr>
</tbody>
</table>

### Onco-Technology

<table>
<thead>
<tr>
<th>Track Chair</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>D.R. Olsen</td>
<td>NO</td>
</tr>
<tr>
<td>C. Moonen</td>
<td>FR</td>
</tr>
<tr>
<td>R. Aebersold</td>
<td>USA</td>
</tr>
<tr>
<td>G. Beer</td>
<td>USA</td>
</tr>
<tr>
<td>H. Boekine</td>
<td>USA</td>
</tr>
<tr>
<td>F. Chen</td>
<td>BE</td>
</tr>
<tr>
<td>W. Enghardt</td>
<td>DE</td>
</tr>
<tr>
<td>R. Neumann</td>
<td>DE</td>
</tr>
<tr>
<td>J.L. Pedraz</td>
<td>ES</td>
</tr>
<tr>
<td>H. von Busch</td>
<td>DE</td>
</tr>
<tr>
<td>C. von Kalle</td>
<td>DE</td>
</tr>
</tbody>
</table>

### Sarcoma: Soft Tissue and Bone

<table>
<thead>
<tr>
<th>Track Chair</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>P. Hegendoom</td>
<td>NL</td>
</tr>
<tr>
<td>P. Schoffski</td>
<td>BE</td>
</tr>
<tr>
<td>V. Budach</td>
<td>DE</td>
</tr>
<tr>
<td>I. Judson</td>
<td>UK</td>
</tr>
<tr>
<td>C. Kantor</td>
<td>FR</td>
</tr>
<tr>
<td>A. Le-Cesne</td>
<td>FR</td>
</tr>
<tr>
<td>P. Reichardt</td>
<td>DE</td>
</tr>
<tr>
<td>J. M. Thomas</td>
<td>UK</td>
</tr>
</tbody>
</table>

### Surgical Oncology

<table>
<thead>
<tr>
<th>Track Chair</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>P. Naredi</td>
<td>SE</td>
</tr>
<tr>
<td>R.A. Audioso</td>
<td>UK</td>
</tr>
<tr>
<td>S. Evrard</td>
<td>FR</td>
</tr>
<tr>
<td>T. Kovacs</td>
<td>HU</td>
</tr>
<tr>
<td>T. Lehner</td>
<td>DE</td>
</tr>
<tr>
<td>M. Leidenius</td>
<td>FI</td>
</tr>
<tr>
<td>G. Poston</td>
<td>UK</td>
</tr>
<tr>
<td>C.J.H. van de Velde</td>
<td>NL</td>
</tr>
</tbody>
</table>

### Symptom Science

<table>
<thead>
<tr>
<th>Track Chair</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>F. Cappuzzo</td>
<td>IT</td>
</tr>
<tr>
<td>M. Di-Palma</td>
<td>FR</td>
</tr>
<tr>
<td>S. Borjesen</td>
<td>SE</td>
</tr>
<tr>
<td>N.I. Cherny</td>
<td>IL</td>
</tr>
<tr>
<td>C. Grau</td>
<td>DK</td>
</tr>
<tr>
<td>E. Patriaki</td>
<td>GR</td>
</tr>
<tr>
<td>E. Ream</td>
<td>UK</td>
</tr>
<tr>
<td>M. Wells</td>
<td>UK</td>
</tr>
</tbody>
</table>

### Translational Research

<table>
<thead>
<tr>
<th>Track Chair</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>F. Cappuzzo</td>
<td>IT</td>
</tr>
<tr>
<td>M. Barbacid</td>
<td>ES</td>
</tr>
<tr>
<td>I. Emberg</td>
<td>SE</td>
</tr>
<tr>
<td>P. Jänne</td>
<td>USA</td>
</tr>
<tr>
<td>M. Krause</td>
<td>DE</td>
</tr>
<tr>
<td>M. Mazieres</td>
<td>FR</td>
</tr>
<tr>
<td>A.H. Ree</td>
<td>NO</td>
</tr>
<tr>
<td>M. Verheij</td>
<td>NL</td>
</tr>
</tbody>
</table>

### Young Oncologists

<table>
<thead>
<tr>
<th>Track Chair</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>E. Martinelli</td>
<td>IT</td>
</tr>
<tr>
<td>E. Martenselli</td>
<td>IT</td>
</tr>
<tr>
<td>D. Gabrys</td>
<td>PL</td>
</tr>
<tr>
<td>P. Bedard</td>
<td>CA</td>
</tr>
<tr>
<td>M. den Dulk</td>
<td>NL</td>
</tr>
<tr>
<td>M. Hudaka</td>
<td>PL</td>
</tr>
<tr>
<td>J. Konings</td>
<td>NL</td>
</tr>
<tr>
<td>C. Massard</td>
<td>FR</td>
</tr>
<tr>
<td>P. Mordant</td>
<td>FR</td>
</tr>
<tr>
<td>L. Moreno</td>
<td>UK</td>
</tr>
<tr>
<td>J. Reis-Fiilho</td>
<td>UK</td>
</tr>
<tr>
<td>S. Rivera</td>
<td>FR</td>
</tr>
<tr>
<td>S. Schüle</td>
<td>DE</td>
</tr>
<tr>
<td>T. Yap</td>
<td>UK</td>
</tr>
</tbody>
</table>

### Paediatric Oncology

<table>
<thead>
<tr>
<th>Track Chair</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>R. Ladenstein</td>
<td>AT</td>
</tr>
<tr>
<td>G. Vassal</td>
<td>FR</td>
</tr>
<tr>
<td>C. Carrié</td>
<td>FR</td>
</tr>
<tr>
<td>M. Gaze</td>
<td>UK</td>
</tr>
<tr>
<td>L.J. Hjorth</td>
<td>SE</td>
</tr>
<tr>
<td>R. Ricardi</td>
<td>IT</td>
</tr>
<tr>
<td>U. Ricardi</td>
<td>IT</td>
</tr>
<tr>
<td>M. Schrappie</td>
<td>DE</td>
</tr>
</tbody>
</table>

### Patient Advocacy/Ethics

<table>
<thead>
<tr>
<th>Track Chair</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>L. Jost</td>
<td>CH</td>
</tr>
<tr>
<td>S. Kyrkides</td>
<td>CY</td>
</tr>
<tr>
<td>A. Adamou</td>
<td>CY</td>
</tr>
<tr>
<td>I. Banks</td>
<td>UK</td>
</tr>
<tr>
<td>R. Catane</td>
<td>IL</td>
</tr>
<tr>
<td>N.I. Cherry</td>
<td>IL</td>
</tr>
<tr>
<td>J. Gessler</td>
<td>DE</td>
</tr>
<tr>
<td>T. Hudson</td>
<td>IT</td>
</tr>
<tr>
<td>A. Kienesberger</td>
<td>AT</td>
</tr>
<tr>
<td>K. Oliver</td>
<td>UK</td>
</tr>
<tr>
<td>E. Verschuur-van der Voort</td>
<td>NL</td>
</tr>
<tr>
<td>A. Waldmann</td>
<td>DE</td>
</tr>
</tbody>
</table>

### Radiobiology/Radiation Physics/Radiotherapy

<table>
<thead>
<tr>
<th>Track Chair</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>J. Bourhis</td>
<td>FR</td>
</tr>
<tr>
<td>D. Zips</td>
<td>DE</td>
</tr>
<tr>
<td>J. Alsner</td>
<td>DK</td>
</tr>
<tr>
<td>J. Bussink</td>
<td>NL</td>
</tr>
<tr>
<td>E. Deutsch</td>
<td>FR</td>
</tr>
<tr>
<td>L.P. Muren</td>
<td>DK</td>
</tr>
<tr>
<td>J. Overgaard</td>
<td>DK</td>
</tr>
<tr>
<td>H.P. Rodemann</td>
<td>DE</td>
</tr>
<tr>
<td>M.C. Vozenin-Brotsch</td>
<td>FR</td>
</tr>
</tbody>
</table>

### Regulatory/Trial Methodology/Pharmacy

<table>
<thead>
<tr>
<th>Track Chair</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>A. Astier</td>
<td>FR</td>
</tr>
<tr>
<td>C. Districh</td>
<td>AT</td>
</tr>
<tr>
<td>J. Carmichael</td>
<td>UK</td>
</tr>
<tr>
<td>P. Hartwig</td>
<td>DK</td>
</tr>
<tr>
<td>D. Lacombe</td>
<td>BE</td>
</tr>
<tr>
<td>P. Lambin</td>
<td>NL</td>
</tr>
<tr>
<td>D. Parkinson</td>
<td>USA</td>
</tr>
<tr>
<td>F. Pignatti</td>
<td>UK</td>
</tr>
<tr>
<td>L. Serfass</td>
<td>FR</td>
</tr>
<tr>
<td>R. Terkola</td>
<td>AT</td>
</tr>
</tbody>
</table>
General Information

Commercially Sponsored Satellite Symposia

The 2011 European Multidisciplinary Cancer Congress Satellite Symposia will take place as follows:

**Friday 23 September 2011**

11:00 – 13:00 Bayer Schering Pharma
   - Dendreon
   - Lilly Oncology
   - MSD Oncology
   - Sandoz International
   - Sanofi-aventis

13:00 – 16:00 Janssen

14:00 – 16:00 Celgene
   - Cephalon
   - Daiichi Sankyo
   - Pfizer Oncology

14:00 – 17:00 Novartis Oncology

17:00 – 19:00 AstraZeneca
   - Baxter
   - Boehringer Ingelheim
   - Novartis Oncology
   - Pfizer Oncology
   - Roche

**Saturday 24 September 2011**

18:30 – 20:00 Amgen
   - Archimedes Pharma
   - Bristol-Myers Squibb
   - Merck Serono
   - Novartis Oncology
   - Pfizer Oncology
   - Pfizer Oncology

**Sunday 25 September 2011**

18:45 – 20:15 Amgen
   - Astellas Pharma
   - AstraZeneca
   - CSK Oncology
   - Merck Serono

18:45 – 22:15 Bristol Myers Squibb

**Monday 26 September 2011**

18:30 – 20:00 Amgen
   - Merck Serono
   - Prime Oncology
   - Sanofi-aventis

Congress Update Service

The *Congress Update Service* is the official Congress e-newsletter which has been specifically designed to help keep you fully informed about the latest Scientific Programme highlights, news and exciting developments. Each monthly newsletter will be archived on the Congress website to consult at leisure.

If you do not automatically receive each issue in your inbox and would like us to email you all future editions please contact us directly via Email at: ECCOcommunications@ecco-org.eu.

Exhibition

The 2011 European Multidisciplinary Cancer Congress Exhibition represents an essential and integral element of the Congress, providing participants with an excellent platform for networking as well as perfect opportunity to gain further insight into cutting edge technology, latest healthcare solutions and services within the oncology field.

The Organising Committee would gratefully like to thank and acknowledge the 2011 European Multidisciplinary Cancer Congress partners for their support and shared insight. To view the list of exhibitors, the latest information surrounding the Exhibition and detailed floor plans please visit: www.ecco-org.eu (‘Congresses and conferences’, ‘2011 Stockholm Cancer Congress’, followed by ‘Exhibition/Sponsorship’).

Entrance is free for all registered participants. The exhibition will be open as follows:

Saturday 24 September 2011 09:30 – 16:30
Sunday 25 September 2011 09:30 – 16:30
Monday 26 September 2011 09:30 – 16:30

Companies, publishers and organisations that would like to participate in the exhibition can download the ‘Invitation to Industry’ from the Congress website: www.ecco-org.eu, or contact Bruno De Man via email: bruno.deman@ecco-org.eu or phone: +32 (2) 775 02 04.
Insurance
The organisers do not accept liability for individual medical, travel or personal insurance and participants are strongly advised to make their own arrangements regarding health and travel insurance.

Language and Translation
The official language of the Congress is English. No simultaneous translation will be provided.

Lunch and Refreshments
Lunch or refreshments are not included as part of the registration fee.

Official Carrier

**STAR ALLIANCE**

*THE AIRLINE NETWORK FOR EARTH.*

**Save up to 20% on travel with the Star Alliance network.**

The Star Alliance™ member airlines are pleased to be appointed as the Official Airline Network for the 2011 European Multidisciplinary Cancer Congress. To obtain the Star Alliance Conventions Plus discounts, please quote the event code SK 09A23 when calling the reservation office of a participating Star Alliance member airline. For booking office information please visit: [www.staralliance.com/conventionsplus](http://www.staralliance.com/conventionsplus)

Registered participants plus one accompanying person travelling to the event can be granted a discount of up to 20%, depending on the fare and class of travel.

The participating airlines for this event will be announced: [www.ecco-org.eu](http://www.ecco-org.eu). Discounts are offered on most published business and economy class fares, excluding website/internet fares, senior and youth fares, group fares and Round the World fares.

**Please note:** For travel from Japan and New Zealand, special fares or discounts are offered by the participating airlines on their own network.

A valid passport is required for entry into Sweden. A visa may be required for some countries. For information about visa and passports contact your local Swedish Embassy at least 3 months prior to your departure to join us in Stockholm.

Transportation
Participants registered for the entire duration of the European Multidisciplinary Cancer Congress are entitled to one free public transport ticket.

Opening Event
The 2011 Stockholm Cancer Congress Opening Event will take place on **Friday 23 September** from 19:30 onwards in Hall A1 of the Congress Centre.

In celebration of the largest and premier cancer meeting in Europe, we invite you to what promises to be an unforgettable evening in the company of friends and guests as well as enjoy a trio of live entertainment followed by a welcome reception serving local fare, delicacies and drinks.
The 2011 Stockholm Cancer Congress: Top 10 Reasons to Attend

1. As of 2011 we are bringing together the 16th ECCO, 36th ESMO, 30th ESTRO Congresses to form the European Multidisciplinary Cancer Congresses. Organised in partnership with ECCO, ESMO, ESTRO, ESSO, EACR, EONS and SIOPÉ, these Congresses are the premier European cancer meetings.

2. They represent the largest European platform at which to present the latest, ground-breaking data with a late breaking submission policy to capture even more abstracts with practice changing data.

3. Global visibility. Building on the media interest and widespread international coverage of our previous Congresses, the 2011 European Multidisciplinary Cancer Congress promises an even stronger media campaign to increase exposure.

4. The European Multidisciplinary Cancer Congresses are European meetings without boundaries. Our 2011 Stockholm Congress will build on the successes of the 2009 Congress which attracted a record, global participation of almost 15,000 from a total of 110 countries.

5. The 33 Scientific Tracks will guarantee the multidisciplinary and multi-professional appeal unique to our Congresses. For the first time ever, we will incorporate 5 brand new Tracks including Industry as well as Oncotechnology.

6. The Comprehensive Scientific Programme of excellence is currently being devised by a record number of over 150 scientific experts, ensuring exceptional quality and educational opportunity.

7. The European Multidisciplinary Cancer Congresses are the largest ACOE/EACCME Accredited events in Europe. ACOE accreditation not only provides delegates with a guarantee of high quality and unbiased educational activity but CME credits gained are recognised by most of the national CME authorities in Europe.

8. Our Congresses are the only European cancer meetings to promote and foster continued improvement at EU Level through a dedicated Oncopolicy Track. Embracing all stakeholders in oncology, the Track is specifically tailored to address and tackle issues of prime importance to the European cancer community head-on.

9. The 2011 Stockholm Congress will of course incorporate the usual favourites including the not-to-be-missed legendary Oxford style debates, educational symposia, the highly topical teaching lectures and much more.

10. Stockholm, capital of Sweden, is synonymous with beauty – ask any of its visitors! Host city to the 2011 European Multidisciplinary Cancer Congress, 23 – 27 September 2011, Stockholm is also treasured for its cultural diversity, architecture, abundant clean and open water, and its many parks. Built on 14 islands and connected by a total of 57 bridges, this captivating city will enchant and entertain us all.
Accommodation & Local Services

Accommodation
MCI - Stockholm Office has been appointed as the official local housing partner for the 2011 European Multidisciplinary Cancer Congress and is offering hotel accommodation, tours and excursions for both groups and individuals.

For information and queries please contact:

MCI – Stockholm Office
Box 6911
SE-102 39 Stockholm
Email: stockholm11@mci-group.com
Tel: +46 8 5465 1500
Fax: +46 8 5465 1599

We kindly ask you to contact the appointed local housing partner DIRECTLY. Please do NOT contact the Congress Secretariat for this information.

Delegates are encouraged to book online via www.ecco-org.eu. All rooms are booked on a first come first served basis.
The deadline for hotel reservation is 1 August 2011. After this date accommodation cannot be guaranteed by MCI – Stockholm Office.

Local Services
Ovation Scandinavia has been appointed to offer a wide range of services during the 2011 European Multidisciplinary Cancer Congress to help you, the participants, make the most of your stay with us in Stockholm!

With extensive experience in event management coupled with a broad network of contacts, companies and service providers locally, you can rely on Ovation Scandinavia to find you the very best.

Just some of the many services that Ovation Scandinavia can organise and manage for you include:

• Transportation
• Meetings (outside the Congress Centre)
• Receptions (outside the Congress Centre)
• Dinners
• Other social events outside the hours of the official Congress Scientific Programme
• On site staff
• Tours
• Room gifts
• Phone rental

For further information, please contact:

Ovation Scandinavia
Tel: +46 (0)8 458 72 70
Email: Scandinavia@ovationdmc.com
Accommodation Form

PLEASE COMPLETE AND RETURN TO:
MCI – Stockholm Office  Email: stockholm11@mci-group.com
PO. Box 6911  Telephone: +46 8 5465 1500
S - 10239, Stockholm, Sweden  Fax: +46 8 5465 1599

HOTEL ACCOMMODATION - DEADLINE: 01 AUGUST 2011
Please note that the organiser would prefer online bookings at: www.ecco-org.eu
PLEASE COMPLETE BY USING TYPEWRITER OR CAPITAL LETTERS

GENERAL DATA - PARTICIPANT
☐ Prof.  ☐ Dr.  ☐ Mr.  ☐ Mrs.  ☐ Ms.  ☐ home address  ☐ work address
Check-in date:..............................  Check-out date:..............................  No. of nights:..............................
Last Name:........................................  First Name:........................................
Institute/Company:..............................  Clinic / Department:..............................
Address:........................................
City:........................................  Postcode:........................................  Country:........................................
International Tel. number:..............................  International Fax number:..............................
Email:........................................

GENERAL DATA – ACCOMPANYING PERSON(S)
Last Name:........................................  First Name:........................................
Last Name:........................................  First Name:........................................

HOTEL ACCOMMODATION

<table>
<thead>
<tr>
<th>Hotel</th>
<th>Category</th>
<th>Single room SEK/night</th>
<th>Double room SEK/night</th>
<th>Walking distance to commuter train</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adlon Hotel</td>
<td>★★★</td>
<td>1895 SEK</td>
<td>2195 SEK</td>
<td>4 minutes</td>
</tr>
<tr>
<td>Anno 1647</td>
<td>★★★</td>
<td>1940 SEK</td>
<td>2390 SEK</td>
<td>15 minutes</td>
</tr>
<tr>
<td>BW Hotel Terminus</td>
<td>★★★★</td>
<td>2005 SEK</td>
<td>n/a</td>
<td>2 minutes</td>
</tr>
<tr>
<td>BW Kom Hotel</td>
<td>(no classification)</td>
<td>1565 SEK</td>
<td>2000 SEK</td>
<td>15 minutes</td>
</tr>
<tr>
<td>Central Hotel</td>
<td>★★★</td>
<td>2280 SEK</td>
<td>2280 SEK</td>
<td>5 minutes</td>
</tr>
<tr>
<td>Comfort Hotel Stockholm</td>
<td>★★★</td>
<td>1795 SEK</td>
<td>n/a</td>
<td>3 minutes</td>
</tr>
<tr>
<td>First Hotel Amaranten</td>
<td>(no classification)</td>
<td>2650 SEK</td>
<td>3350 SEK</td>
<td>10 minutes</td>
</tr>
<tr>
<td>First Hotel Reisen</td>
<td>(no classification)</td>
<td>2850 SEK</td>
<td>3150 SEK</td>
<td>15 minutes</td>
</tr>
<tr>
<td>Hotel Esplanade</td>
<td>★★★★★</td>
<td>1895 SEK</td>
<td>n/a</td>
<td>20 minutes</td>
</tr>
<tr>
<td>Hotel Hellsten</td>
<td>★★★★★</td>
<td>2390 SEK</td>
<td>2490 SEK</td>
<td>20 minutes</td>
</tr>
<tr>
<td>Hotel Riddargatan</td>
<td>★★★★★</td>
<td>2020 SEK</td>
<td>2390 SEK</td>
<td>20 minutes</td>
</tr>
<tr>
<td>Hotel Skeppsholmen</td>
<td>(no classification)</td>
<td>2415 SEK</td>
<td>3185 SEK</td>
<td>20 minutes</td>
</tr>
<tr>
<td>Lady Hamilton Hotel</td>
<td>(no classification)</td>
<td>3190 SEK</td>
<td>3690 SEK</td>
<td>15 minutes</td>
</tr>
<tr>
<td>Lord Nelson Hotel</td>
<td>(no classification)</td>
<td>2090 SEK</td>
<td>2390 SEK</td>
<td>15 minutes</td>
</tr>
<tr>
<td>Nordic Sea Hotel</td>
<td>(no classification)</td>
<td>2050 SEK</td>
<td>n/a</td>
<td>3 minutes</td>
</tr>
</tbody>
</table>
The table of hotel options and rates includes:

<table>
<thead>
<tr>
<th>Hotel</th>
<th>Category</th>
<th>Single Room SEK/night</th>
<th>Double Room SEK/night</th>
<th>Walking Distance to Commuter Train</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radisson Blu Royal Viking</td>
<td>★★★★★</td>
<td>3095 SEK</td>
<td>3295 SEK</td>
<td>1 minute</td>
</tr>
<tr>
<td>Rex Hotel</td>
<td>★★★★</td>
<td>1990 SEK</td>
<td>2290 SEK</td>
<td>15 minutes</td>
</tr>
<tr>
<td>Rica Hotel Gamla Stan</td>
<td>★★★</td>
<td>2095 SEK</td>
<td>2195 SEK</td>
<td>15 minutes</td>
</tr>
<tr>
<td>Rica Hotel Kungsgatan</td>
<td>★★★★★</td>
<td>1895 SEK</td>
<td>n/a</td>
<td>5 minutes</td>
</tr>
<tr>
<td>Rica Hotel Stockholm</td>
<td>★★★★★</td>
<td>1895 SEK</td>
<td>n/a</td>
<td>5 minutes</td>
</tr>
<tr>
<td>Scandic Malmen</td>
<td>(no classification)</td>
<td>2190 SEK</td>
<td>2590 SEK</td>
<td>6 minutes</td>
</tr>
<tr>
<td>Scandic Norra Bantorget</td>
<td>(no classification)</td>
<td>1890 SEK</td>
<td>1990 SEK</td>
<td>5 minutes</td>
</tr>
<tr>
<td>Zinkendamms Hotel</td>
<td>★★★</td>
<td>1735 SEK</td>
<td>2035 SEK</td>
<td>6 minutes</td>
</tr>
</tbody>
</table>

**Special requests** (i.e. type of room, sharing double room with):

---

Rates are given in SEK, include breakfast buffet, service and 12% VAT. Further information and a city map can be found at: www.ecco-org.eu.

**Please note**: as the Congress takes place during a busy period in Stockholm we recommend you arrange your accommodation at your earliest convenience.

**GUARANTEE/PAYMENT**
No reservation will be confirmed unless MCI has received your credit card details as a guarantee of your hotel reservation. All hotel costs are to be settled directly with the hotel.

**Please note**: the deadline for hotel reservation is **August 1, 2011**. After this date available rooms or the preferential rate cannot be guaranteed. In the event of the preferred hotel or room type being fully booked, MCI reserves the right to book another alternative available. Once MCI has confirmed your room, the reservation is considered guaranteed.

**CANCELLATION**
Until July 17, 2011: Cancellation fee of SEK 500 per cancelled room. As from July 18, 2011 and until August 5, 2011: Cancellation fee representing 50% of the value for the cancelled nights. As from August 6, 2011: Cancellation will be charged with a cancellation fee representing 100% of the value for the cancelled nights. The cancellation fee, if any, will be charged to your credit card mentioned below.

**CREDIT CARD GUARANTEE AND PAYMENT OF CANCELLATION FEE:**

- Eurocard/Mastercard
- Diners Club
- Visa
- American Express

Card no: .......................................................... Expiry Date: ..........................................

Owner’s name as shown on the card: .......................................................... Control/CVV-Code: ..............................

Date: .......................................................... Card Owner’s signature: ..............................
SAVE UP TO 20% ON GETTING TO YOUR CONVENTION WITH CONVENTIONS PLUS

It's easy to save money on your flights if you fly the Star Alliance™ network. Simply quote the event code SK03A23 when you make your booking with any Star Alliance member airline and you'll automatically get a discount of up to 20%.

The Star Alliance network has 27 member airlines with over 21,000 flights a day so we can offer you a lot more choice when planning your travel. For more information about our member airlines and contact details, please visit our website at www.staralliance.com/conventionsplus
LET’S THINK

BOEHRINGER INGELHEIM IS COMMITTED TO ONCOLOGY AND ADVANCED RESEARCH IN THE AREAS OF:

- Angiogenesis Inhibition
- Signal Transduction Inhibition
- Cell-Cycle Kinase Inhibition

www.inoncology.com